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ABSTRACT 
 
 Tau is a protein which regulates microtubule stability and is heavily involved in 
axonal transport.  This stability is dynamically controlled in part by over 40 
phosphorylation sites across the tau protein which allows for binding and release from 
the microtubules. However, if abnormal hyperphosphorylation occurs, tau dissociates 
from the microtubules. Once released, the microtubules become unstable and the 
aberrant tau mislocalizes from the axon to the somatodendric compartment, where it 
aggregates. These aggregates are made of many pathological forms of tau including 
oligomeric species, paired helical filaments, and neurofibrillary tangles, all of which have 
associated toxicities. Tau pathology is a hallmark of Alzheimer’s disease, one of over 15 
diseases known as tauopathies which present with tau pathology, all of which lack 
effective treatments. Heat shock protein 90 kDa (Hsp90) is a major adenosine 
triphosphate (ATP)-dependent regulator of non-native proteins, like misfolded tau. 
Although Hsp90 is able to effectively refold and degrade many aberrant proteins, it has 
been associated with preserving aberrant tau.  In fact, inhibiting the Hsp90 ATPase 
activity leads to the degradation of tau, which has been demonstrated in a number of 
models with the use of various Hsp90 inhibitors. However, there are many side-effects 
associated with the use of these inhibitors including toxicity and heat shock factor 1 
(HSF1) activation. Although improvements on Hsp90 inhibitors are still in progress, this 
study explores targeting Hsp90 through a slightly different mechanism, by targeting 
ix 
 
Hsp90 co-chaperones.  Hsp90 is involved in almost every pathway in each cell 
throughout the body. Co-chaperone proteins assist Hsp90 in these various processes, 
but are each only involved in a subset of the total Hsp90 interactome.  Therefore, 
targeting Hsp90 co-chaperones could lead to improved efficacy, potency, and safety of 
drugs designed toward Hsp90 for the treatment of tauopathies. We previously showed 
one of these co-chaperones, FK506 binding protein 51 kDa (FKBP51), a 
tetratricopeptide repeat (TPR) domain containing immunophilin, coordinates with Hsp90 
to regulate tau metabolism. More specifically, we found that increases and decreases in 
FKBP51 levels correlated with increases and decreases in tau levels, respectively.   
 FKBP51 knockout mice have been extensively studied and have shown no 
negative phenotypes in these characterizations. In this study, we found that this mouse 
model has decreased endogenous tau levels. Furthermore, this study demonstrates that 
FKPB51 colocalizes with pathological tau in the AD brain, and synergizes with Hsp90 to 
preserve tau from proteasomal degradation.  Additionally, FKBP51 overexpression in 
mouse model of tau pathology leads to the preservation of tau. We went on to 
characterize this accumulated tau as being neurotoxic and oligomeric in nature, while 
being low in silver positive, β-sheet structure. In the human brain, we found that 
FKBP51 is strikingly increased with aging and even further in the AD brain. In support of 
these findings, we also found age-associated decreased methylation in the FKBP5 
gene, which encodes FKBP51. Moreover, we found that increasing levels of FKBP51 
caused other co-chaperone to have reduced Hsp90 binding and led to tau preservation.  
This supports a model where age-related increases in FKBP51 lead to the preservation 
of misfolded tau species and ultimately disease. 
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 In order to model the high FKBP51 expression found in the aging brain, we 
generated the first FKBP5 overexpressing mouse model, which is tet-regulatable. This 
mouse, rTgFKBP5, was made by targeted, single insertion of the human FKBP5 gene 
into the HIP11 locus of the mouse genome crossed with CamKIIα tTa mice. We have 
now confirmed high FKBP51 levels in the forebrain and hippocampus of this mouse, 
which will serve as a testing platform for FKBP51 regulating drugs.  
Overall, this work exemplifies FKBP51 as an important regulator of tau 
metabolism through Hsp90. With the absence of a negative phenotype in mice ablated 
of FKBP51 and the development of this novel, FKBP51 overexpressing mouse model, 
strategies designed to decrease FKPB51 levels or to disrupt the FKBP51/Hsp90 
complex could be relevant for the treatment of tauopathies, like AD. 
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CHAPTER ONE: 
RATIONALE FOR TARGETING HSP90 THROUGH CO-CHAPERONE PROTEINS 
FOR THE TREATMENT OF ALZHEIMER’S DISEASE 
 
1.1 Abstract  
The microtubule stabilizing protein, tau, becomes hyperphosphorylated and 
accumulates in neurological diseases, called tauopathies.  The most common tauopathy 
is Alzheimer’s disease (AD) which has no cure.  Chaperone proteins in the cell, like heat 
shock protein (Hsp) 90 kDa, work in large complexes to direct tau triage. Hsp90 does no 
act on client proteins alone, but instead corporates with a wide variety of co-chaperone 
proteins. Small molecule inhibitors of Hsp90 have been shown to successfully clear tau, 
predominantly phospho-tau species, making Hsp90 inhibitors are a promising 
therapeutic intervention for tauopathies, like AD. However with many off target effects, 
due to the many functions of Hsp90 complexes, further development to increase 
specificity, potency and permeability is needed. This chapter discusses the most current 
developments in Hsp90 inhibitors including blood-brain barrier permeability and 
decreased toxicity. Additionally, targeting Hsp90 through co-chaperone proteins with be 
discussed, with an emphasis on developments in targeting FKBP51, an Hsp90 co-
chaperone, to increase specificity in targeting tau. 
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1.2 Introduction 
Molecular chaperones are a family of proteins involved in the regulation of other 
protein in the cell1. Many of these chaperones are heat shock proteins (Hsp) which 
regulate processes from the folding of nascent chain proteins, to the refolding and 
degradation of misfolded proteins2. Hsp90 is a ubiquitous chaperone protein which 
utilizes ATP to perform regulatory functions in almost every pathway in the cell3,4. Hsp90 
is comprised of a nucleotide binding domain at the N-terminus, a client and co-
chaperone binding site in the middle domain, and a C-terminal dimerization domain5. 
This highly conserved protein has two cytosolic and two organelle bound forms, all of 
which work together to maintain cell homeostasis6. The inducible cytosolic Hsp90 is 
known as Hsp90α and the inducible form is termed Hsp90β, however not much more is 
known about the differences between these two forms. Even less studied are the 
organelle-bound Hsp90s, which include the endoplasmic reticulum (ER) resident 
glucose-regulated protein 94 (GRP94) and the mitochondrial associated tumor necrosis 
factor receptor associated protein 1 (TRAP1)7. Thus, this chapter will focus on 
therapeutics designed to target cytosolic Hsp90.  
Although Hsp90 has been shown to properly refold aberrant proteins, it has been 
shown to lead to the preservation of pathological tau. In fact, inhibiting the ATPase 
domain of Hsp90 has been previously shown to be effecting at stimulating tau 
degradation8,9. Tau normally functions to stabilize the microtubules, however in disease 
state, becomes hyperphosphorylated and misaggregates leading to 
neurodegeneration10. Aggregation of tau is a hallmark in Alzheimer’s disease (AD) and 
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other neurological diseases, called tauopathies11,12. Since Hsp90 actually facilitates 
increases the accumulation of tau, and under certain conditions, Hsp90 can enhance 
tau toxicity13. Thus, small molecule inhibitors of Hsp90 have been generated to 
regulated tau biology. Since there the two terminal domains of Hsp90 both contain 
ATPase activity, small molecule inhibitors have been made towards each end and 
inhibit Hsp90 in different steps of protein refolding14.  Furthermore, Hsp90 inhibitors 
which bind to the N-terminus activate heat shock factor 1 (HSF1) which regulates the 
expression of other chaperones such as Hsp70 and Hsp279 and inhibitors which bind to 
the C-terminus do not activate HSF1. Hsp90 inhibition through either route is effective at 
decreases tau levels15. There have been many advances in building small molecule 
inhibitors toward the ATPase activity of Hsp90. This chapter will discuss these recent 
improvements on both N-terminus specific and C-terminus specific inhibitors. 
 Cytosolic Hsp90 works as a large protein complex, with other chaperones and 
co-chaperones to maintain homeostatic balance within the cell. While Hsp90 is a part of 
complexes which have roles in the folding and degradation of many important clients in 
a number of processes, Hsp90 co-chaperones play a more targeted role in these 
cellular processes16. There are two classes of these proteins, those which bind to 
Hsp90 via a tetratricopeptide (TPR) domain and those which do not contain this 
domain7. The TPR containing co-chaperones that will be discussed include carboxy-
terminus of the Hsp70-interacting protein (HIP), Hsp70-Hsp90 organizing protein (HOP), 
heat shock cognate 70-interacting protein (CHIP), and the TPR containing co-
chaperones which display peptidyl-prolyl isomerase (PPIase) activity, including: protein 
phosphatase 5 (PP5), FKBP52, and FK506 binding protein 51kDa (FKBP51)17. While 
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other Hsp90 co-chaperones without a TPR domain are able to bind to Hsp90 including 
Aha1 and cell division control 37kDa (Cdc37)18,19. This chapter will focus on the known 
effects of Hsp90 modulation on tau, as depicted in Figure 1.1. Chemicals that are 
known to modulate both Hsp90 and its co-chaperones will be discussed, with a 
particular emphasis on the immunophilin FKBP51.  
 
1.3  New developments in cytosolic Hsp90 inhibitors 
Although, inhibitors have now been identified for each ATPase domain of Hsp90, 
the first class to be really developed was those targeting the N-terminus, which has a 
classical ATP domain14. In addition to inhibiting the ATPase activity of the N-terminus, 
these inhibitors activate heat shock factor 1 (HSF1), which subsequently leads to the 
elevation of Hsp27 and Hsp709. However, both N-terminal and C-terminal targeting 
Hsp90 inhibitors are able to effectively decrease tau levels. This chapter will focus on 
the recent advances in the identification and development of these inhibitors.  
The first Hsp90 inhibitor to be identified was the antibiotic geldanamycin (GA)20. 
GA treatment has been shown to preferentially reduce phosphorylated tau21, but had a 
poor toxicity profile22. Moreover, disease-like states increase the binding of these 
geldanamycin scaffold inhibitors to Hsp9023, which was shown to rapidly degrade tau in 
a mouse model of tauopathy24. Improvements on this antibiotic were made to increase 
the potency and reduce toxicity leading to the second generation of Hsp90 inhibitors.  
These new inhibitors included the well-known and markedly less toxic analog, 17-
(allylamino)-17-demethoxygeldamycin (17-AAG). However, even with increased blood-
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brain barrier (BBB) permeability, this development was not able to increase the 
bioavailability of these compounds.  
The purine scaffold has generated many more N-terminal targeting Hsp90 
inhibitors. One of these inhibitors, EC102, is BBB permeable and was shown to potently 
reduce tau levels in a human tau mouse model9. The more newly developed, purine 
based PU scaffold, including PU24FCl, includes compounds which are highly soluble in 
water8. Studies have clearly shown these inhibitors to be effective towards the ATPase 
activity of Hsp9025; however, studies looking at the effects on tau biology have not been 
reported to date. Therefore, N-terminal Hsp90 ATPase inhibitors show promising results 
in reducing tau levels, especially with increased BBB permeability. However, off-target 
effects of these compounds still remain, including eliciting a strong heat shock 
response26. 
The C-terminal inhibitors, which do not activate HSF1, were originally based off 
of the novobiocin scaffold27. KU-32 and A4 were developed from improvements on this 
base scaffold22,28. While C-terminal inhibitors are available, not much information is 
known about the regulation of tau biology from C-terminal Hsp90 inhibition. However, 
recent work has shown this class of inhibitors could prove effective at regulating tau 
degradation29. 
 
1.4  Targeting Hsp90 co-chaperones increases specificity  
Hsp90 triages non-native proteins by either refolding or targeting for degradation.  
These roles are carried out through the help of a number of Hsp90 co-chaperones.  
Some Hsp90 co-chaperones are associated with refolding client proteins, Aha1, Cdc37, 
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PP5, FKBP51, FKBP52, and HOP30-32; inversely, some co-chaperones are known to be 
biased towards the degradation of client proteins like CHIP. Hsp90 co-chaperone 
complexes have been shown to diversely modulate tau by our laboratory and 
others10,13,33-36. The Sansalvamide A scaffold, which prevents the binding of co-
chaperone proteins to the C-terminus of Hsp90,  is a promising set of compounds to 
target Hsp90 co-chaperone interactions37. The McAline lab recently synthesized 
derivatives which differentially regulate co-chaperone binding to Hsp9038. However, the 
potency of these drugs towards tau reductions has not been determined. Derivatives 
from this scaffold or other co-chaperone modulating drugs could allow for targeting of 
Hsp90 through more potent, less off-target drugs4. Although many co-chaperones have 
not been well studied in regards to tau, they could provide new directions for future 
research.  
Aha1 is a one of a kind co-chaperone which stimulates Hsp90 ATPase activity39. 
Our lab previously showed that tau levels are decreased upon Aha1 knockdown18, 
however, not much more is known in relation to tau biology. Additionally there are no 
specific inhibitors are available for Aha1, but Aha1 may be a good target to design 
therapeutics towards for effectively regulating tau through Hsp90. 
Cdc37, studied most for its role in refolding kinases, was previously shown by our 
lab to correlate with tau levels36. In words, this study showed that tau preservation was 
increased upon Cdc37 overexpression and inversely, tau levels were depleted when 
Cdc37 was knocked-down. There are two inhibitors of the Hsp90/Cdc37 complex 
Celastrol40 and Withaferin A41,42. Studies using either of these drugs lead to decreases 
in tau levels while activating HSF143,44.  Since Hsp27 and Hsp70 were induced and both 
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regulate tau biology15, it is difficult to determine the direct effect of targeting Cdc37.  
More experiments will need to be done to determine if the Cdc37/Hsp90 complex is a 
good target in regulating tau. 
Hop facilitates the transfer of clients between Hsp70 and Hsp90 through its three 
TPR domains45. Previous work has shown that tau levels inversely correlate to Hop18. 
Although, C9, an Hsp90/Hop specific inhibitor has been identified46, no studies have 
been performed to determine the effects on tau biology.   
Unlike the previous mentioned co-chaperones, there has been extensive studies 
looking at the effects of the E3 ubiquitin ligase, CHIP, on stimulating tau degradation9,47. 
A study using CHIP knockout mice revealed mice ablated for CHIP show higher tau 
levels than wild-type littermates48. Therefore the development of drugs which stimulate 
the expression of CHIP or increase its binding to Hsp90 may lead to reduced tau levels. 
 
1.4.1 Hsp90 and PPIases 
The importance of PPIase proteins regulating tau biology was first by Pin149.  
This important family functions to isomerize cis-trans conformation of phospho-
serine/threonine-proline motifs and regulate their phosphorylation 50. Recently, work 
from our lab and others has shown that other PPIases, such as FKBP51 and FKBP52 
can also regulate tau metabolism13,35,51-53. Unlike Pin1, the PPIase proteins which will 
be discussed function though binding to Hsp90, however similar to Pin1 they may be 
effective at regulating tau metabolism.  
One member of the protein phosphatase family, PP5, regulates the 
phosphorylation of many important pathways54-59. We previously reported that knocking-
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down PP5 led to decreased tau levels18. Additionally, PP5 was previously shown to 
regulate tau phosphorylation60. Therefore, drugs which stimulate PP5 activity or lower 
PP5 levels may prove to negatively regulate tau levels. 
The Hsp90/FKBP52 complex has been well characterized for its role in the 
regulation of steroid hormone complexes61. However, there is quite a bit is also known 
about the regulation of tau biology by FKBP52.  The Baulieu lab elegantly showed that 
FKBP52 can directly bind to tau and preferentially bind to hyperphosphorylated, 
pathogenic tau species52. Furthermore, this study showed that this interaction had a 
functional effect on tau. That is when FKBP52 was bound to tau; tau was no longer able 
to stabilize the microtubules. In a study from our lab, we found that FKBP52 knockdown 
preferentially increased total tau, but not phospho-tau18. In a more recent study, the 
Giustiniani et. al. found that FKBP52 interacted with tau to produce tau oligomers53, 
similar to the results our lab found with FKBP51 and tau13.   
Similar to FKBP52, FKBP51 is most well studied as a part of steroid hormone 
complexes62. However, we have found that FKBP51 has a role in tau biology13,35. The 
FKBP51 protein is comprised of two domains (FK1 and FK2) which are FKBP-like and 
exhibit PPIase activity63, which allow for the direct binding of immunosuppressive drugs 
like FK506, rapamycin, and cyclosporin64.  This FKBP-like domain, which is found 
similarly in other immunophilins, makes identifying drugs which specificity bind to one 
FKBP protein quite difficult. Furthermore, targeting the FKB-like domain would block the 
binding of progesterone receptor and AKT (protein kinase B). Moreover, FKBP51 
contains a TPR domain, which permits binding to glucocorticoid receptors (GR), 
FKBP51, androgen receptors, and two pleckstrin homology domain and leucine-rich 
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repeat protein phosphatases (PHLPP1 and PHLPP2). Drugs designed towards this TPR 
domain could be beneficial at preventing most of the association of FKBP51 with tau 
through Hsp90. Furthermore, targeting this domain would prevent association of 
FKBP51 with GR, which may lead to effective regulation of this steroid hormone, which 
is known to have deleterious effects in AD and other psychiatric diseases65-67. 
There is ubiquitous expression of the FKBP5 gene in most cell types68 and 
tissues of the body69. FKBP51 is highly expressed in T-cells and neurons in the brain 
and can localize to both the cytoplasm and nucleus of the cell. FKBP5 expression is 
induced upon activation of the hypothalamic-pituitary adrenal (HPA) axis70. FKBP51 is 
most well-known for the important role it plays in regulating GR transactivation.  
FKBP51 is part of a short, negative feedback loop activated by GR which leads to 
FKBP51 upregulation. This acts to slow the activity of GR by decreasing the affinity of 
GR for glucocorticoids71. 
Recent studies have linked numerous single nucleotide polymorphisms (SNPs) in 
FKBP5 to increased risk for PTSD72, major depressive disorder (MDD)73, aggressive 
behavior 74, suicide 75, immune dysfunction76, and psychosis 77. These SNPs are 
associated with increased FKBP5 expression. We recently showed increased 
expression of FKBP51 in AD, but no SNP has been linked to this disease 13. A SNP 
which is fairly common among many of the psychiatric diseases, rs1360780, is the only 
SNP to have a known functional effect on FKBP5, where the T risk allele allows for 
stronger binding to the TATA box protein leading to a two-fold increase in FKBP51 
protein78.   
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Fujii et al. showed that a T risk allele for the common SNP rs1360780 was able 
to regulate the expression of both FKBP5 and GR in humans exposed to a 
dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test. Interestingly, the 
regulation of FKBP5 and GR was age-dependent and mimicked what has been 
measured in PTSD patients79.  This correlates with what is seen in FKBP5-/- mice, 
where a phenotype can be found only under conditions of stress or aging.   
FKBP5 is located on the short arm of chromosome 6, which has many genes that 
have identified polymorphisms associated with cancer80, rejections of transplantations81, 
and autoimmune disease82. The FKBP5 SNP rs1360780 was shown to have significant 
linkage disequilibrium with human leukocyte antigen (HLA)-DR6, a chromosome 6 gene 
linked to inflammation and transplant outcome83. This ancestral haplotype was 
associated with resistance to glucocorticoids. For a more comprehensive chapter on 
SNPs found in FKBP5 and associated diseases see Zannas and Binder 201384. 
In addition to brain-related diseases, targeting FKBP51 has also been of 
therapeutic interest in pancreatic cancer. Decreasing FKBP51 levels with shRNA 
suppressed tumor growth through dephosphorylation of AKT, an effect mediated by 
PHLPP85. In a separate study, the genetic variant rs73748206 was found to have a 
positive correlation with chemoresistance in pancreatic cancer86. AKT phosphorylation 
is common to many cancers; targeting this pathway by decreasing FKBP5 expression or 
FKBP51 levels would be of interest in many forms of cancer. In the interest of AD, AKT 
activation also has been shown to contribute to tau phosphorylation likely through 
PAR1/MARK2. Additionally, suppression of AKT leads to lower CHIP levels, which in 
turn would increase tau levels, by decreasing tau degradation by the ubiquitin 
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proteasome system87. A detailed look at role FKBP51 plays in the regulation of tau by 
AKT and CHIP has yet to been explored.  
Multiple groups have been involved in characterizing mice ablated for FKBP51, 
the FKBP5-/- mouse model. These studies have showed no detectible negative 
phenotypes associated with knocking-out FKBP5188,89. Moreover, these studies 
demonstrated that mice ablated for FKBP51 actually show less depressive-like 
episodes than wild-type mice in behavior tests when they are stressed or aged. This 
work exemplifies that targeting FKBP51 through therapeutics is likely to have few 
negative side effects. Recent work from our lab showed that there is a clear increase in 
FKBP5 expression with aging in the human brain13. This age-dependent increase is also 
present in murine brain tissue35,89. The mechanism by which FKBP5 expression is 
increased over time is partially due to demethylation of the FKBP5 gene. Demethylation 
of the FKBP5 gene has been shown in chronic corticosterone treatment in mice90 and in 
the human brain in psychiatric diseases like PTSD91.  There are many genes which are 
up regulated with age in the brain, many are a part of the inflammatory and stress 
response systems, along with those regulating DNA repair and synaptic plasticity92.  
However, our previous study showed that Hsp90 and other Hsp90 co-chaperones 
STUB1 (CHIP) and FKBP4 (FKBP52) did not share a similar increase with age, like 
FKBP513. This age related increase in FKBP5 expression correlates with age dependent 
cognitive decline. Additionally, high FKBP5 expression in the brain is been linked to 
decreased hippocampal volume. FKBP5 has also been shown in many studies to 
increase NF-ĸB.  The inhibition of this protein was recently shown to increase lifespan in 
a Drosophila model93. Thus, decreasing FKBP51 levels may mimic the increased 
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lifespan seen by the NF-ĸB inhibitor, pyrrolidine dithiocarbamate (PDTC) and, inversely, 
increased levels may lead to accelerated aging13,91. 
FKBP51 is well characterized for its immunosuppressive effects in T-cells 
through suppression of calcineurin, a protein phosphatase, when bound to FK506 or 
other immunosuppressive drugs64. However, drugs targeting this region of FKBP51 may 
be capable of inducing similar immune suppressing effects, which could lead to 
susceptibility to other unnecessary infections.  Alternatively, the TPR domain of 
FKBP51, which facilitates the binding of Hsp90 and steroid hormones, could be used as 
the target for rational drug design. It was found that inactivating the PPIase domain of 
FKBP51 did not change the regulation of GR in a non-human primate model94; targeting 
the TPR domain may be more effective at regulating this process. Lastly, protein 
complexes, such as the FKBP51/Hsp90/GR complex or a combination of those 
proteins, could be potential therapeutic targets. A GR reporter gene assay is 
commercially available to assess changes in GR activity and can be used in the 
screening of small molecules95. 
Therefore, there is a lot known about FKBP51 biology, and there are many tools 
available to aid in the design drugs which specifically target FKBP51.  This includes 
having a full crystal structure which has been solved63,96. However, with about 70% 
share sequence homology with FKBP52 a specific drug will still be difficult to identify97. 
Taken together, this shows that more work is needed to identify the domain of FKBP51 
which is most important to target for its interactions with tau and GR. Moreover, this 
work exemplifies the need to develop new therapeutics for targeting FKBP51. 
 
 
 
13 
 
1.5  Conclusions 
The major chaperone Hsp90 presents a desirable target for therapeutics to 
regulate tau biology. This major chaperone is just that, a major regulator of many 
processes throughout the cell and all throughout the body. Studies have clearly 
demonstrated that inhibition of Hsp90 leads to the clearance of many tau species, but 
this inhibition is linked to many off target effects. Some of these side effects are even 
toxic, which is not very surprising for targeting an essential, ubiquitous protein. Recent 
developments in Hsp90 inhibitors have increased specificity for homologues of Hsp90, 
lower toxicity, and increased preference for pathological tau. This is hopeful for the 
generation of viable Hsp90 therapeutics, but increased specificity for Hsp90 regulated 
pathways may lead to more promising results. Co-chaperones of Hsp90 assist in more 
specified pathways, but there are few drugs available which specifically regulate these 
Hsp90 co-chaperone complexes.  One of these co-chaperones, FKBP51, could be an 
ideal target for tau altering therapeutics. Given the absence of a negative phenotype in 
mice ablated for the FKBP5 gene, drugs designed to lower the levels of FKBP51 or the 
Hsp90/FKBP51 complex could be able to alter tau levels with limited side effects.  
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Figure 1.1. A schematic of the degradation of tau through Hsp90 modulation. The 
metabolism of the microtubule associated protein tau can be modulated through Hsp90 
regulation via Hsp90 co-chaperones and inhibitors. Tau becomes hyperphosphorylated 
in disease and forms oligomers and tangles. Hsp90 inhibitors block the release of 
clients, like tau, leading to proteasomal degradation, while Hsp90 co-chaperones have 
differential effects on tau metabolism. Co-chaperones with TPR domains bind to the C-
terminus of Hsp90, as do some Hsp90 inhibitors. However, the majority of Hsp90 
inhibitors bind the N-terminal domain.  
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CHAPTER TWO1: 
 
ACCELERATED NEURODEGENERATION THROUGH CHAPERONE-MEDIATED 
OLIGOMERIZATION OF TAU 
 
2.1 Abstract 
 
Aggregation of tau protein in the brain is associated with a class of 
neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa 
(FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that 
prevents tau degradation. In this study, we have shown that tau levels are reduced 
throughout the brains of FKBP5-/- mice. Recombinant FKBP51 and Hsp90 synergized 
to block tau clearance through the proteasome, resulting in tau oligomerization. 
Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 
preserved the species of tau that have been linked to Alzheimer's disease (AD) 
pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. 
Alterations in tau turnover and aggregate structure corresponded with enhanced 
neurotoxicity in mice. Our data support a model in which increased FKBP51 levels and 
its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at 
attenuating FKBP51 levels or its interaction with Hsp90 has the potential to be 
therapeutically relevant for AD and other tauopathies. 
 ____________________ 
1Portions of this work were previously published (Blair LJ et al, 2013) and are used with 
permission of the publisher. 
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2.2 Introduction 
Neurofibrillary tangles, hallmarks of a class of neurodegenerative diseases 
termed tauopathies, are comprised of microtubule-associated tau protein aggregates 
that persist in the brain even after neuron death11. In the most common tauopathy, 
Alzheimer’s disease (AD), the presence of these tangles correlates with pathological 
development and disease progression. However, levels of neuronal death in AD far 
exceed what is expected based on the observed numbers of tau tangles98, suggesting 
that a different mechanism is primarily responsible for neurodegeneration. One possible 
explanation for this discrepancy is that soluble tau species not visible by standard 
histological methods are the main cause of neurotoxicity in tauopathies99. In fact, 
neurons may form tangles as a protective mechanism to sequester these more toxic 
soluble intermediates and convert them into a less harmful form100,101. These soluble tau 
species may also be able to spread from neuron to neuron in a fashion similar to prions, 
further establishing their role in perpetuating pathogenicity102-104.  
Mutations in MAPT, the gene encoding tau, can also lead to the production of 
soluble tau conformers with pathogenic potential, leading to rarer tauopathies such as 
progressive supranuclear palsy (PSP) and frontal temporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17)105-107. Thus, identifying the mechanisms that 
contribute to the production of soluble tau intermediates could be paramount for 
developing therapeutic approaches to treat AD and other tauopathies.  Since tau 
dysfunction is somehow precipitated from within the neuron, chaperones may play a 
central role in preserving or even facilitating tau conformations that can lead to its 
toxicity.  
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Chaperone proteins, like major chaperone Heat shock protein 90 kDa (Hsp90), 
play major roles in the triage of de novo and non-native protein species, such as 
refolding or degrading misfolded tau4. Hsp90 works as part of a large protein complex 
with co-chaperones which interact when bound to specific targets3.  We previously 
found that one of these co-chaperones, FK506-binding protein 51 kDa (FKBP51), coded 
by FKBP5, interacts with Hsp90 to preserve tau in the cell35 and that knock-down of 
FKBP5 dramatically decreases tau levels.   
FKBP51 is an immunophilin with peptidyl-prolyl isomerase activity, which also 
has a tetratricopeptide (TPR) region which allows for direct binding to Hsp9064.  We 
sought to identify a major mechanism by which FKBP51 could work with Hsp90 to 
prevent tau degradation. Our findings suggest that FKBP51 synergizes with Hsp90 to 
preserve tau degradation by the 20S proteasome and maintains this tau in a toxic, low 
β-sheet content, oligomeric state.  
 
2.3 Materials and methods 
2.3.1 Ethics statement 
All studies were carried out following the guidelines set by the University of South 
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AALAC) regulations.   
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2.3.2 Materials 
Antibodies: pT231 (Anaspec), Tau V-20 (Santa Cruz Biotechnology), PHF1 (pS396/404; 
gift from Dr. Peter Davies,  The Feinstein Institute for Medical Research, Manhasset, 
NY), CP13 (pS202/t205; gift from Dr. Peter Davies), Tau12 (N-Terminal 2-18; gift from 
Dr. Lester Binder, Northwestern University, Chicago, IL), pT231 (Abcam), NeuN 
(Millipore), Neurotrace (Invitrogen), H150 (Santa Cruz), GFP (Invitrogen), T22 (Dr. 
Rakez Kayed, University of Texas Medical Branch, Galveston, TX), Hsp90 (BD 
Biosciences), GAPDH (Meridian Life Science), FKBP51 (gift from Marc Cox), and 
FKBP51 (Cell Signaling) 
Viruses: Adeno-associated virus serotype (AAV) 9 FKBP5 (Dr. Todd Golde, University 
of Florida, Gainesville, FL) and AAV9 EGFP (gift from Dr. Kevin Nash, University of 
South Florida, Tampa, FL) were obtained for murine gene therapy studies. 
Human Tissue: Human tissue was obtained from the University of California at Irvine 
MIND Alzheimer’s disease Research Center (Irvine, California). 
 
2.3.3 Western and dot blot analysis 
 Samples extracted from brain tissues were analyzed by Western blotting using 
10% acrylamide gels43. Antibody dilutions were 1:1000 unless otherwise stated. All 
secondary antibodies were used at 1:1000 (Southern Biotech). Blots were developed 
using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare). For dot blots, proteins 
were applied onto a wet nitrocellulose membrane, rinsed three times with phosphate 
buffered saline, and dried by vacuum.  Once dry, membrane was blocked and 
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developed as described above. For T22 dot blots with recombinant protein, 50ng of tau 
was the minimum required for T22 detection. 
 
2.3.4 Protein purification 
 Production and purification of recombinant proteins was based on protocols 
described previously108. Briefly, WT 0N4R tau, FKBP51, Hsp90α was cloned into pET28 
vectors containing an N-terminal polyhistidine tag. Proteins were expressed in E. coli, 
and purified via Ni–NTA–Sepharose chromatography. With the exception of FKBP51, all 
proteins were subsequently purified by size-exclusion chromatography with a Superdex 
200 column.  Verification by Coomassie Brilliant Blue-stained SDS polyacrylamide gels 
was used to determine the purity of all proteins. 
 
2.3.5 20S proteasome assay 
6μg 20S proteasome (ENZO Life Sciences) was incubated with 1μM ON4R-Tau 
(final volume 10μl) for the 5 minutes in reaction buffer at 37°C (50mM Tris pH 7.5, 
50mM KCl, and 0.2mM DTT).  FKBP51 and HSP90 (concentrations are indicated in 
figure) were added in lanes indicated.  FKBP51 and HSP90 were pre-incubated with tau 
for 5 minutes prior to addition of 20S proteasome.  Reactions were stopped by adding 
laemmli buffer and boiling 4 minutes.  Samples were then resolved on a 15% SDS-
PAGE gel and analyzed by Western blot.  To determine if FKBP51 inhibited 20S activity 
100μg Suc-LLVY-AMC was incubated with 6μg of 20S proteasome for 5 minutes at 
37°C.   Readings were then taken with an excitation wavelength of 380nm and an 
emission wavelength of 460nm. 
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2.3.6 Circular dichroism spectroscopy 
 Far- UV circular dichroism (CD) measurements were performed on a JASCO J-
815 spectropolarimeter.  The proteins (WT 0N4R tau, FKBP51, Hsp90) were dialyzed 
overnight in 10mM sodium phosphate buffer, pH 7.5 and the concentration was 
determined using a commercially available BCA kit (Pierce).  The proteins were mixed 
prior to transfer to a 1mm quartz cuvette and measured at 25oC.  Each spectrum is the 
average of 3 scans from 190-260nm at a rate of 50nm/min.  Control curves from buffer 
alone were subtracted for each experiment.  The calculated spectrums were determined 
by simple addition of the indicated individual protein spectrums.   
Tau aggregation measured by dynamic light scattering and Thioflavin T fluorescence 
 All proteins were dialyzed overnight into buffer containing 20 mM Tris-HCl and  
100 mM NaCl at pH 7.4. The concentrations of purified tau, FKBP51, Hsp90α were 
determined using the UV extinction coefficients at 280nm of 0.155, 0.788, 0.700, and 
0.694 M-1 cm-1 respectively 109. 
 Recombinant P301L tau (300 μM) was combined with FKBP51 and/or Hsp90 at a 
stoichiometric ratio of 50 parts tau to 1 part FKBP51 and/or 1 part Hsp90.  All proteins 
were filtered through a 0.2 μm syringe filter (Anotop) and a 100 kDa molecular cutoff 
filter (Nanosep). Hsp90 and FKBP51 required an additional filtration through a 0.02 μm 
filter (Anotop). Heparin sodium salt (MP Biomedicals LLC cat#194114) was filtered 
through a 0.2 μm and 0.02 μm syringe filter and added at 75 µM to initiate aggregation. 
Samples were placed in a Greiner Bio-One 384 well glass-bottom plate (cat# 781892), 
incubated at 37°C, and aggregation kinetics in each well were monitored for 3 min every 
2 hours using a Wyatt DynaPro DLS Plate Reader Plus. The low molar ratios of 
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FKBP51 or Hsp90 to tau ensured that the DLS correlation function was dominated by 
the scattering of tau. Mean aggregate radius were plotted as a function of time using 
Igor Pro and fitted using the sigmoidal curve described by the following equation: 
𝑅ℎ = 𝑅ℎ(𝑚𝑖𝑛) +  𝑅ℎ(𝑚𝑎𝑥)1 + exp([𝑡ℎ𝑎𝑙𝑓 − 𝑡] 𝜏)⁄  
where thalf is the time in days to reach half the maximum aggregate radius and the 
apparent rate constant, kapp is equal to 1/ 𝜏.  Thus, a larger apparent rate constant 
indicates a faster increase in aggregation110.    
 After incubation at 37oC for 6 days, Thioflavin T (ThT) fluorescence was 
measured by removing the sample and diluting 30 fold into 10 μM ThT. The maximum 
fluorescence intensity was measured at 485 nm with an excitation of 445 nm using a 
FluoroMax-4 Spectrofluorometer (Horiba Jobin Yvon, Edison, NJ).  Data from 3 dilutions 
of each sample was averaged and normalized to a tau only control that was set at 
100%. 
 
2.3.7 AFM characterization of tau/Hsp90/FKBP51 aggregate morphology 
 Samples from the day 6 time point of the DLS measurements were diluted 1:10 
in polymerization buffer, deposited onto freshly cleaved mica for 15 min, rinsed with 
deionized water, and dried with dry nitrogen. Mounted samples were imaged in air with 
an MFP-3D atomic-force microscope (Asylum Research) using PPP-FMR silicon tips 
(Nanosensor) with a nominal tip radii of 7 nm. The cantilever was driven at 60–70 kHz in 
alternating current mode at a scan rate of 0.5 Hz. Images were acquired at 1024x1024 
pixel resolution. 
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2.3.8 Cell culture and transfection 
N2A cells were cultured in Opti-Mem plus media supplemented with 10% FBS and 1% 
Penicillin-Streptomycin (Invitrogen). Primary neurons were harvested from P0 pups as 
previously described (74). Briefly, newborn pups were immersed in 70% EtOH and 
rapidly decapitated. Intact brains were removed and stored in dissociation buffer 
containing HBSS supplemented with 1% sodium pyruvate, 0.1% glucose, and 10mM 
HEPES (pH 7.3). Following removal of the meninges, brains were cut into small pieces 
with a razor blade. Neurons were trypsinized and suspended in a single cell solution in 
MEM media supplemented with 10% FBS, 0.45% glucose, 1% 100mM sodium  
pyruvate, 1% 200 mM glutamax, and 1% Penicillin/Streptomycin. Cells were plated on a 
96 well plate and grown for two weeks in Neurobasal media supplemented with 1% B-
27, 1% 200mM glutamax, and 1% Penicillin/streptomycin. 
 
2.3.9 MTS assay 
Primary neurons in 96 well plates were transduced for 14 days. N2A cells were plated in 
96 well plates and transfected for 48 hours. At the end of the experiments MTS assays 
(Promega) were performed. Replicate wells of no less than 8 replicates for each 
treatment were analyzed. 
 
2.3.10 Animals 
  The FKBP5 -/- colony was bred and genotyped as previously described89. The 
rTg4510 colony was bred and genotyped as previously described101.  Four month old 
rTg4510 (n=5) and wild-type littermates (n=5) were stereotaxically injected bilaterally 
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into the hippocampus at X= ±2.7 Y= -2.7 Z= +3.0. Each injection delivered 2 μL of 
adeno-associated viral particles serotype 9 tagged with either green fluorescent protein 
(GFP) or FKBP51.  After 2 months of expression, mice were perfused with 0.9% saline.  
Brains were immediately fixed with 4% paraformaldehyde overnight. Following sucrose 
gradients up to 30%, tissue was sectioned using a sliding microtome into 0.2% sodium 
azide in PBS. Sections for general histochemical staining were sectioned at 25 μm. 
Additionally, 50 μm sections were taken for stereology. 
 
2.3.11 Immunohistochemistry  
Free floating staining was performed as previously described111. Briefly, sections 
were incubated in PBS supplemented with 10% methanol/3% H202 to block 
endogenous peroxidases. Following PBS washes, tissue was permeabilized by 0.2% 
Triton X-100 with 1.83% lysine and 4% serum in PBS, after 30 minutes, tissue was 
incubated at room temperature in primary antibody. Tissue was incubated overnight 
with either anti-pT231 tau (1:300), anti-FKBP51 (1:1000), or T22 (1:700). Following 
three washes, biotinylated goat anti-rabbit (Southern Biotech) secondary (1:10000) was 
added for 2 hours. Prior to peroxidase development, an ABC kit (Vectastain) was used 
to increase visibility. Following washes, tissue was incubated with 0.05% 
diaminobenzidine plus 0.5% nickel and developed with 0.03% H202. Sections mounted, 
allowed to dry overnight and dehydrated in alcohol gradients. Slides were coverslipped 
with DPX following clearing by Histoclear. Sections stained with cresyl violet (nissl) were 
incubated with 0.05% cresyl violet briefly and quickly destained with 0.3% acetic acid in 
water prior to dehydration. One series of sections was stained by immunofluoresence. 
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This tissue was permeabilized as described above and incubated overnight with anti-
Tau V-20 (1:50), anti-PHF1 (1:1000), anti-biotinylated NeuN (1:100), and anti-FKBP51 
(1:300) or anti-GFP (1:300) respective to the injected virus. Following washes, sections 
were incubated for 2 hours with goat anti-rabbit (1:3000), donkey anti-goat (1:1000), 
and streptavidin (1:1000) AlexaFluor tagged secondary antibodies.  Sections stained 
with Neurotrace (1:25) (Invitrogen) were incubated following secondary for 20 minutes.  
Human tissue was incubated in 0.1% Sudan Black B in 70% EtOH (Sigma) to 
reduce auto-fluorescence for 20 minutes and then washed three times with 0.2% Tween 
in PBS following fluorescent secondary. Tissue was mounted after three washes and 
coverslipped with ProLong Gold antifade (Invitrogen) reagent. Gallyas silver stain was 
performed as previously described for non-paraffin imbedded tissue112.  
Sections stained for stereology were blocked and permeabilized as described 
above and incubated overnight with biotinylated NeuN (1:3000) at room temperature.  
Following washes, ABC conjugation, and peroxidase development tissue was mounted 
on glass slides and dried overnight. A cresyl violet counterstain was applied to the 
slides as described before coverslipping. 
 
2.3.12 Microscopy 
A slide scanning microscope (Mirax) was used to image all brightfield stained 
tissue.  Fluorescent microscopy was performed using a Leica TCS SP2 laser scanning 
confocal microscope. Fields of view were selected in the hippocampus based on the 
spread of the virus. Using a 63x/1.40-0.60 PLAN APO Oil objective, a minimum of 15 1 
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μm Z-stacked images was collected from sections taken from each animal with Argon 
and HeNe lasers.  
 
2.3.13 Imaging analysis 
Bright field analysis was performed using NearCYTE whole slide image analysis. 
We used this program to outline regions of interest from the entire slide. Thresholds 
were then manually set until all of the positive cells, as determined by the analyzer, 
were selected while as little non-specific areas were selected as possible. Using the 
batch process option, each stained group was automatically calculated for the Area 
Ratio of positive cells within the determined regions of interest. 
Fluorescent image analysis was performed using ImageJ as previously described 
with minor modifications113. Briefly, images were opened and channels separated 
(Red=Tau, Green=FKBP51, and Blue=NeuN) using the Bio-Formats plug-in.  
Background was subtracted from the Green and Red channels using the Gaussian Blur 
tool (Radius = 50um) of the image and subtracting this new image from the original 
image. Both the Green and Red channels were despeckled and a binary mask was 
made of the Blue channel. Using the image calculator, we created a new image that 
represented all neurons (Blue) and also FKBP51/GFP expressing (Green).  Next, using 
Analyze>Set measurements: we redirected this new image of only infected neurons to 
the red (tau) channel. Individual cells were accounted for by using Analyze> Analyze 
Particles and a radius of 50 to infinity. We then used the mean of the area and the 
intensity density to determine the amount of tau (red) in those cells. 
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To calculate the effect of the virus on all surrounding neurons, the same images 
were used. We cleaned up the red channel by using background subtraction and 
despeckling the images. A mask was made of all the neurons shown by the blue 
channel. This mask was redirected to the red channel and the particles were analyzed 
(100-infinity) to measure the area fraction of the red within the blue. This would tell us 
how much tau was in each neuron in images taken that had virus expression in at least 
one cell.  Comparisons were made of the total area fraction between the FKBP51 and 
GFP injected. 
 
2.3.14 Stereology  
 Neurons were defined by NeuN and cresyl violet staining, those positive for both 
were counted in the CA3. Using a computerized stereological system, connected to an 
Leica DM4000B microscope with a Prior motorized stage, the area was outlined using 
distinct landmarks in the brain using 4x magnification114,115. Neurons were counted in 
this region by randomly designated areas in the computer generated grid using a 100x 
oil immersion lens.  Neurons, as defined by NeuN and nissl staining, were counted 
when they were randomly located within the three-dimensional dissectors or touching 
the inclusion lines.  The top and bottom 1 μM of tissue was excluded. The tissue 
thickness was determined to be 10.48 ± .028 μM for all sections analyzed. 
 
2.3.15 Statistics 
 To compare 2 groups, a student’s t-test was used.  Groups larger than 2 were 
evaluated using a 1-way ANOVA test. P values below 0.05 were considered significant. 
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2.4 Results 
2.4.1 FKBP51 depletion reduces tau levels in brain 
 Previous work showed that FKBP51 depletion reduced tau levels in cell models 
of tauopathy35. However, it was not clear whether this was relevant in vivo. To address 
this issue, brain tissue from FKBP5 knockout mice was collected and subjected to both 
immunohistochemical and biochemical analyses. Mice were generated as previously 
described89,116. Staining of FKBP5 -/- revealed a significant reduction in tau levels 
throughout the brain (Figure 2.1, A-C). Similarly, Western blot analyses of brain 
homogenates showed a similar reductions in several tau epitopes, including a 
significant reduction in total tau (as assessed with the Tau 12 [amino acids 2-18] and 
H150 [tau N terminus] antibodies) and phosphorylated tau (as assessed with the CP13 
[pS202] and pT231 [PHF6] tau antibodies) (Figure 2.1, D-E). We then performed 
fluorescent analyses to confirm that FKBP51 and tau were co-localized in neurons in 
human brain. Immunostaining with FKBP51 antibody and PHF1 (pS396/S404 tau) 
antibody that stains human AD brain well, combined with a neuronal marker showed co-
localization of neuronal tau pathology and FKBP51 in AD cortex (Figure 2.2).  
 
2.4.2 FKBP51 works with Hsp90 to synergistically block the 20S proteasome from 
degrading tau  
Previously we reported that FKBP51 coordinated with Hsp90 to promote the 
accumulation of non-ubiquitinated tau in the presence of a proteasome inhibitor35. This 
suggested that FKBP51 may be playing a role in ubiquitin-independent tau degradation 
via the 20S proteasome, a process shown to be a major route of tau clearance117,118. 
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The 20S proteasome serves as the catalytic core for the 26S proteasome119, and 20S 
proteasomes can be about 3-4 times more abundant in cells than 26S proteasomes120. 
In addition, FKBP51 was previously found to slow the degradation of tau by 
chymotrypsin, the major protease of the 20S proteasome35. To determine unequivocally 
whether the FKBP51/Hsp90 complex could alter the kinetics of clearing tau by the 20S 
proteasome, we used a reconstituted in vitro assay as previously described117. Indeed, 
tau was rapidly degraded by the 20S proteasome but this was partially blocked by 
FKBP51 alone (Figure 2.3A). When Hsp90 and FKBP51 were combined, tau 
degradation by 20S proteasome was completely blocked (Figure 2.3, B-C), whereas 
Hsp90 alone had effects on tau similar to that of FKBP51 alone. The effects of FKBP51 
and Hsp90 together were significantly greater than the additive effects of each 
individually, suggesting true synergy (Figure 2.3D). Changes in degradation were not 
attributed to non-specific alteration of the 20S proteasome, as the 20S reporter 
substrate was not affected by the addition of FKBP51 (Figure 2.3E). Thus, FKBP51 and 
Hsp90 synergized to prevent 20S proteasome-mediated tau clearance, implicating that 
this chaperone complex not only is involved in tau turnover, but also suggests a novel 
mechanism for FKBP51 in regulating intracellular 20S proteasome substrates.  
 
2.4.3 FKBP51 coordinates with Hsp90 to produce non-amyloid, ThioflavinT-negative tau 
oligomers  
 The synergistic effects of Hsp90 and FKBP51 directly on tau proteasomal 
degradation suggested that these two chaperones somehow worked together to 
regulate tau conformation and possibly its aggregation kinetics. To get a general idea 
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about how FKBP51 and Hsp90 regulated tau structure, circular dichroism (CD) analyses 
were performed with tau in combination with FKBP51, Hsp90 or both proteins together. 
As previously shown, tau is an intrinsically disordered protein, and its CD spectra has a 
minima at 200nm121. Indeed, the tau produced in our lab reproduced these results, 
showing a spectrum from 190 to 260nm, typical for a highly disordered protein such as 
tau (Figure 2.4A).  The secondary structures of FKBP51 and Hsp90 were also 
determined by CD. Consistent with previous reports, FKBP51 and Hsp90 showed 
substantial ordered secondary structure122,123. The PONDR-FIT algorithm, one of the 
most accurate disorder predictors 124 confirmed the CD data, indicating that tau is 
almost completely disordered while FKBP51 and Hsp90 are largely ordered (Figure 
2.5). Next, CD spectra were collected for tau in the presence of FKBP51 alone, Hsp90 
alone, or both chaperones combined (Figure 2.4B). The dashed lines in Fig 2.4B show 
the predicted spectra of these protein mixtures if no structural change were to occur. 
These calculated spectral plots were obtained by summing the spectra from each of the 
individual measurements taken for tau, FKBP51, or Hsp90; however, the observed CD 
spectra (Figure 2.4B, shown as solid lines) were in contrast to the calculated spectra, 
suggesting that structural changes were occurring when these proteins were combined. 
While FKBP51 alone (3:10 ratio of FKBP51 to tau) had no effect on the secondary 
structure of tau (Figure 2.4B), Hsp90 (2:10 ratio of Hsp90 to tau) did alter tau structure. 
Interestingly, when FKBP51, tau, and Hsp90 were incubated together at a respective 
3:10:2 ratio, tau showed a unique structural change unlike incubation with Hsp90 or 
FKBP51 alone, suggesting that FKBP51 only affected tau structure when Hsp90 was 
present.   
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Since altering the structure of aggregation-prone proteins is known to contribute 
to their pathogenic assembly into fibrillar structures125-128, we speculated that Hsp90 
alone and Hsp90 with FKBP51 could alter tau fibril assembly.    We used dynamic light 
scattering (DLS) to assess how the Hsp90/FKBP51 complex was regulating the kinetics 
of global tau aggregation113.  For these studies, tau aggregation was induced with 
heparin sulfate in the presence of either Hsp90 or FKBP51 alone, and in the presence 
of Hsp90 and FKBP51 together. A 50:1 tau:chaperone ratio was used to minimize any 
contributions of the chaperones themselves to the signal produced. Tau combined with 
these Hsp90/FKBP51 mixtures was allowed to polymerize over a period of 6 days and 
particle size distributions were determined with DLS throughout the duration of the 
experiment. Similar to the results using CD spectroscopy, FKBP51 alone did little to 
impact tau aggregation kinetics; both tau alone and tau with FKBP51 reached the half-
maximal size by 2.3 ± 0.3 days (Figure 2.6A). The rate of aggregation was also 
unaffected (kapp = 1.7 ± 0.3 days -1). Hsp90 alone actually accelerated tau aggregation 
(time for half-maximal size, thalf = 1.5 days ± 0.0; apparent rate, kapp = 3.3 ± 0.0 days -1) 
consistent with previous findings 129. Surprisingly, though, FKBP51 was able to slow the 
Hsp90-induced tau aggregation (time for half-max size, thalf = 2.1 ± 0.1 days; apparent 
rate, kapp = 2.0 ± 0.5 days -1)(Figure 2.6B), further supporting our hypothesis that 
FKBP51 uses Hsp90 to regulate tau biology and specifically promote its pathogenesis. 
Incubating these tau aggregates with Thioflavin T, a dye that specifically recognizes β-
pleated sheet amyloid structure, showed that Hsp90 promoted tau β-sheet aggregates, 
but FKBP51 prevented this (Figure 2.6B). Therefore, FKBP51 prevents tau from 
adopting β-sheet structure in the presence of Hsp90, promoting the production of 
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amorphous tau aggregates. These results were confirmed using atomic force 
microscopy (AFM) (Figure 2.6C). To determine whether recombinant tau was indeed 
forming oligomeric structures, tau was incubated with FKBP51 or Hsp90 alone or with 
FKBP51 and Hsp90 together with Heparin as described for the DLS experiment. The 
mixtures of these proteins were then analyzed by dot blot with the anti-tau oligomer 
specific antibody, T2299.  Indeed, T22 positive tau was only observed in the presence of 
FKBP51. The production of this oligomeric species was enhanced, even though total 
tau levels were the same, when FKBP51 and Hsp90 were incubated together with tau 
(Figure 2.6D). Hsp90 alone produced no T22 immuno-reactivity. In this way, FKBP51 
causes Hsp90 to alter its structural influence on tau, leading to the formation of non-
amyloid tau aggregates and oligomeric tau species, which have both been implicated as 
the primary toxic tau species that facilitate neurodegeneration100,101,130,131. Based on 
these findings, we speculated that FKBP51 over-expression in the brain may drive tau 
toxicity. Therefore, we sought to evaluate the effects of FKBP51 in vivo. 
 
2.4.4 In vivo, FKBP51 overexpression preserves tau species, including oligomers 
The hippocampi (HPC) of a cohort of 4-month-old rTg4510 transgenic mice, 
which express human P301L mutant human tau, were injected bilaterally with AAV9 
particles expressing either FKBP51 (n=5) or GFP (n=5).   These mice have abundant 
Hsp90 levels and low basal FKBP51 levels at 6 months of age, and they are the best 
model to recapitulate human tau pathobiology101,111,130,132,133. Therefore, 2 months 
following these injections, 6 month-old mice were harvested and examined histologically 
as previously described111. FKBP51 expression was observed in the hippocampus; 
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however the AAV did not transduce all neurons (Figure 2.7A).  Due to this typical 
limitation of AAV use, a fluorescent masking technique previously developed by our lab 
was utilized to evaluate the levels of tau in neurons expressing the AAV product, in this 
case FKBP51 or GFP113. Triple immunofluorescent staining of sections for FKBP51, 
total tau, and the neuronal marker NeuN revealed that the amount of tau found within 
FKBP51-positive neurons was significantly increased compared to tau levels in neurons 
overexpressing GFP (Figure 2.7, B-C). In fact upon further analysis of the site 
surrounding the injection site, the levels of phosphorylated tau throughout the CA3 
region were significantly higher in mice injected with FKBP51 compared to those 
injected with GFP (Figure 2.8, A-B). Based on our in vitro results, tissue was then 
stained with oligomeric tau antibody T2299. T22 tau was significantly increased in the 
CA3 of FKBP51 injected mice, compared to GFP injected littermates (Figure 2.8, C-D), 
indicating that FKBP51 was preserving tau in an oligomeric state.  To further confirm the 
accumulation of tau by FKBP51 in vivo, homogenized tissue from FKBP51 or GFP 
AAV9 injected mice was analyzed by Western blot and dot blot (Figure 2.9A).  Both 
phospho-tau (pT231) and total tau (H150) were significantly preserved in mice injected 
with FKBP51 AAV9 particles compared to GFP AAV9 injected littermates.  In addition, 
T22 oligomeric tau was significantly preserved in mice overexpressing FKBP51 (Figure 
2.9B). 
 
2.4.5 FKBP51 prevents tangle formation, but enhances tau neurotoxicity  
Our in vitro data suggested that FKBP51 also prevented amyloid formation. The 
rTg4510 mouse is one of the only transgenic models to produce Gallyas-silver positive 
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tangles that are a traditional pathological hallmark for AD and other tauopathies111. 
Gallyas silver stains the same structure as ThT134, but Gallyas lacks the fluorescent 
properties of ThT. Thus, the previous characterization of Gallyas silver in this model 
combined with its lack of fluorescence in the GFP spectrum made it the ideal stain to 
assess ß-sheet structure in these studies. Silver positive tau was significantly reduced 
in the CA3 region of mice injected with FKBP51 AAV compared to those injected with 
GFP AAV (Figure 2.10, A-B). Thus, FKBP51 over-expression in neurons promoted the 
accumulation of non-amyloid oligomeric tau species, similar to what was observed in 
vitro.  
The toxicity of these T22-positive/silver-negative tau species produced by 
FKBP51 over-expression were then directly evaluated using unbiased stereology. 
Indeed, in rTg4510 mice expressing FKBP51, there was a significant decrease in the 
number of neurons in the CA3 hippocampal region compared to mice injected with GFP 
AAV (Figure 2.11, A-B).  This neuron loss did not significantly alter CA3 volume (Figure 
2.11C).  Since this was the first time FKBP51 and tau have been shown to be 
neurotoxic, we performed in vitro experiments to confirm this result. Primary neurons 
from tau expressing pups were transduced with FKBP51 AAV9 particles and allowed to 
express for 14 days. On the 14th day, an MTS assay was performed to measure toxicity. 
Significant toxicity was found in tau expressing neurons transduced with FKBP51 AAV9 
compared to GFP AAV9 transduced controls (Figure 2.12A). Additionally, Neuro2A 
cells, a mouse neuroblastoma line, were transfected with tau, FKBP51, or the 
combination for 48 hours. MTS assays performed at the end of the 48 hours revealed 
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significant cell toxicity in the neuronal line, but only in the cells transfected with tau and 
FKBP51 together (Figure 2.12B). 
 
2.5 Discussion 
We have found that a chaperone, FKBP51, can work with Hsp90 to produce 
oligomeric tau in the brain, facilitating its neurotoxicity. FKBP51 over-expression 
enhanced neuronal loss in the rTg4510 tau transgenic mouse model, suggesting that 
FKBP51 coordinates with Hsp90 to prevent tau clearance and facilitate its toxicity. This 
provides further evidence that other forms of tau, besides those that are pathologically 
visible in post-mortem tissue like tangles, are highly neurotoxic101,130,135,136. Thus factors 
that facilitate FKBP51 expression could promote an environment in the aging brain that 
supports tau pathogenesis.  
At the molecular level, these studies show that FKBP51 can prevent tau 
clearance through the 20S proteasome without directly impairing 20S proteasomal 
activity. This is one of the few examples where chaperones can coordinately interact 
with a substrate, in this case tau, to block its degradation. This type of control of tau 
degradation may be unique to tau because of its high level of disorder137. Since the 20S 
proteasome typically proteolyzes unfolded proteins120, it is possible that FKBP51 and 
Hsp90 bind tau, giving it more order and preventing its indiscriminate degradation 
through the 20S proteasome. But this appears to come at a price: FKBP51 and Hsp90 
also promote a structure for tau that produces toxicity, supporting the idea of the need 
for balance in the proteostasis network for healthy neuronal aging and function138. When 
chaperone levels are too high or too low, some substrates that are particularly difficult to 
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handle can begin to accumulate and cause disease. These substrates can then have 
detrimental consequences to the proteostasis system and general cellular health139-142.  
Perhaps the most intriguing result from these studies is the discovery that a 
chaperone can mediate the formation of tau oligomers. These data also show that 
subverting amyloid formation with chaperones could produce a deleterious 
consequence. Recent work has begun to question the role of amyloids in AD 143. While 
amyloid pathology (tangles, plaques, Lewy bodies, etc) is the hallmark of many 
neurodegenerative diseases, these types of pathologies do not correlate well with 
neuronal loss or dysfunction in animal models of disease. For example, in the rTg4510 
tau transgenic mice, neurons with tau tangle structures are longer lived100,144. This same 
model displays cognitive recovery when tau is suppressed, despite continued tangle 
formation101,131. Moreover, strategies that deplete soluble intermediate tau species 
without impacting tangle pathology have been very successful at improving cognitive 
impairment and neuronal loss in transgenic tau models101,131,145. The current evidence 
suggests that sequestration of misfolded or abnormally folded proteins into amyloid β-
sheet structures may be more beneficial to neurons than allowing these intermediates to 
traverse the intracellular milieu146-148. FKBP51 not only interferes with tau degradation 
and promotes tau oligomer formation, but it also impairs its ability to be sequestered into 
less toxic tangles, facilitating tau toxicity. This is why strategies aimed at depleting 
FKBP51 or inhibiting its association with tau or Hsp90 may be highly effective for tau-
based therapeutics.  
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Figure 2.1. Tau expression is decreased in the FKBP5-/- mice. Representative 
images of brain tissue from (A) wildtype and (B) Fkbp5 -/- mice stained for pT231 tau 
and corresponding sections without primary. Scale bar:  2000 μm. (C) Quantification of 
pT231 stain. *p=0.0097 (D) Representative Western blot of brain homogenates from 
Fkbp5-/- mice probed for CP13 (pS202/pT205), Tau12 (total tau), pT231 tau, H150 
(total tau), and GAPDH. (E) Quantification of duplicate Western blots (±SEM). *p<0.05 
for CP13, Tau 12 (total tau), and H150 (total tau) ***p<0.001 for pT231. 
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Figure 2.2. Tau associates with FKBP51 in the AD brain. (A) Fluorescent micrograph 
of human cortex stained with FKBP51, PHF1 (pS396/pS404), and Neurotrace (neuronal 
nuclei) antibodies (Original magnification, x60). Scale bar: 50μm.  
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Figure 2.3. FKBP51 and Hsp90 synergistically prevent tau degradation by the 20S 
proteasome. (A) Tau was incubated alone, with 20S proteasome, or with FKBP51 and 
20S proteasome for 5 minutes. (B) Tau was incubated alone, with 20S proteasome, with 
FKBP51, and with Hsp90 with or without FKBP51 for 5 minutes. (C) Relative tau levels 
(± SEM) in each sample using 1 μM Hsp90. **P < 0.01, ***P < 0.001. (D) Tau levels (± 
SEM) following incubation with FKBP51 and Hsp90 in the presence of the 20S 
proteasome (green). Calculated tau levels (blue) from the addition of the results of tau 
preserved following incubation with Hsp90 and with the tau preserved following 
incubation with FKBP51 in the presence of the 20S proteasome. *P < 0.05. (E) FKBP51 
was incubated with 100 μg Suc-LLVY-AMC and 20S proteasome for 5 minutes. OD 
readings (± SEM) were taken at 460 nm. 
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Figure 2.4. FKBP51 and Hsp90 alter the secondary structure of tau. (A) CD spectra 
of tau, FKBP51, and Hsp90 recombinant protein. CD spectra were obtained at protein 
concentrations of 10 μM tau, 2 μM FKBP51, and 3 μM Hsp90 in 10 mM sodium 
phosphate buffer (pH 7.5) at room temperature. (B) CD spectra readout of tau incubated 
with FKBP51, Hsp90, or both (solid lines). Calculated (calc) CD spectra (dashed lines) 
from the addition of each protein’s spectra shows what the readout would display if 
there were not protein interactions.  
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 Figure 2.5. Evaluation of intrinsic disorder propensity of human tau protein. Tau 
(A), FKBP51 (B), and Hsp90 (C) by disorder predictor PONDR-FIT. The light pink, cyan 
and yellow shadows around the corresponding PONDR-FIT curves show the statistical 
error of PONDR-FIT predictions.  
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Figure 2.6. FKBP51 and Hsp90 combine to produce oligomeric tau structures. 
Measurements of tau filament formation were monitored daily for 6 days, with a reading 
taken at least every 16 hours. (A) Tau fibril assembly was measured (± SEM) using DLS 
in the presence of FKBP51, Hsp90, and both combined. DLS measurements of tau 
filament formation were monitored daily for 6 days, with a reading taken at least every 
16 hours. (B) Tau was stained with Thioflavin T (ThT) to show β-pleated sheet 
aggregation after 6 days of incubation alone or with FKBP51, Hsp90, or both combined 
(± SEM). ***P < 0.0001. (C) Atomic force microscopy images of tau multimers. The 
product of the DLS was imaged using atomic force microscopy for conformation. Both 
height (black) and amplitude (gray) images are shown. Scale bar: 0.5 μm. (D) 
Recombinant proteins were applied to a dot blot after 6 days, with heparin incubation at 
a ratio of 35 parts tau to 1 part chaperone combination. This was probed with T22 and 
H150 (total tau) antibodies.  
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Figure 2.7. FKBP51 overexpression by viral vector in rTg4510 mice preserves tau. 
(A) GFP or FKBP51 was overexpressed in the HPC of rTg4510 mice using an AAV9 
vector. Scale bar: 2,000 μm; 50 μm (inset). Original magnification, ×63 (inset). B) Total 
tau (± SEM) was measured using ImageJ in neurons expressing FKBP51 or GFP. At 
least 15 images were taken per animal. ***P < 0.0001. (C) Representative images 
FKBP51- and GFP-expressing neurons (arrows) (original magnification, ×63) using 
antibodies toward GFP (green), FKBP51 (green), total Tau (red), and NeuN (blue). 
Scale bar: 50 μm.  
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Figure 2.8. FKBP51 overexpression preserves phospho- and oligomeric tau 
species.  (A) Tissue from injected mice was stained for pT231 tau. pT231-positive area 
(± SEM) was measured per CA3. *P = 0.0463. (B) Representative sections are shown. 
Scale bar: 2,000 μm; 200 μm (inset). Original magnification, ×10 (inset). (E) T22 
oligomeric tau (± SEM) was measured in the CA3 region of FKBP51- and GFP-
overexpressing mice. *P = 0.0176. (D) Representative sections are shown. Scale bar: 
2,000 μm; 200 μm (inset). Original magnification, ×10 (inset).   
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Figure 2.9. Biochemical analysis of rTg4510 mice overexpressing FKBP51 or GFP. 
(A) Representative Western blot of brain homogenate from FKBP51- or GFP-AAV–
injected mice immunoblotted with FKBP51, pT231, H150 (total tau), and GAPDH. T22 
antibody is on complimentary dot blot. (B) Quantification of Western blots (± SEM). #P = 
0.03, pT231; *P = 0.05, H150 (total tau); **P = 0.002, T22.  
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Figure 2.10. FKBP51 overexpression decreases the accumulation of silver-
positive tau. (A) Sections from FKBP51- and GFP AAV–injected mice were stained 
with Gallyas silver stain and positive area (± SEM) per CA3 was measured. *P = 
0.0297. (B) Representative images of each group are shown. Scale bar: 2,000 μm; 200 
μm (inset). Original magnification, ×10 (inset).   
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Figure 2.11. FKBP51 selectively promotes tau neurotoxicity. (A) Neurons stained by 
cresyl violet and NeuN were counted (± SEM) by stereology in the CA3 region. *P = 
0.0003. (B) Representative images are shown. Scale bar: 500 μm; 50 μm. Original 
magnification, ×20 (inset). (C) Volume of CA3 (± SEM) in injected transgenic mice was 
evaluated by stereology.  
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Figure 2.12. FKBP51 is neurotoxic. (A) Murine primary neurons from tau mice were 
treated with FKBP51 or GFP AAV9. **p=0.0041 (B) Neuro-2A cells were transfected 
with 6TR, P301L tau, FKBP51, or both P301L and FKBP51. **p=0.0064 Toxicity was 
measured colormetrically by MTS assay.   
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CHAPTER THREE1: 
FKBP5 IN THE AGING AND ALZHEIMER’S DISEASE BRAIN 
 
3.1 Abstract 
FK506 binding protein 51kDa (FKBP51/FKBP5) is part of a mature heat shock 
protein 90kDa (Hsp90) chaperone complex that preserves tau. We have previously 
shown that in brains devoid of FKBP51, tau levels are reduced and that high expression 
of FKBP51 leads to toxic, oligomeric tau species.  In this study, FKBP51 levels in 
human brains were found to selectively increase with age and Alzheimer’s disease, 
which correlated with demethylation of the regulatory regions in the FKBP5 gene. 
Moreover, FKBP51 levels significantly correlated with Braak pathological staging. We 
propose a model where age-associated increases in FKBP51 levels can out-compete 
the association of other pro-degradation Hsp90 co-chaperones, resulting in tau 
oligomers. Thus, development of drugs which target FKBP51 or related complexes 
could be therapeutically relevant for Alzheimer’s disease and other tauopathies. 
 
 
 
 
 
____________________ 
1Portions of this work were previously published (Blair et al, 2013)  and are used with permission of the 
publisher. 
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3.2 Introduction 
Alzheimer’s disease (AD) is an age associated disorder hallmarked by the 
misfolding and subsequent accumulation of amyloid β (Aβ) plaques and tau 
neurofibrillary tangles149. One important measure of AD progression, known as Braak 
staging, is measured post-mortem by the accumulation of tau, since tau accumulation is 
the best correlated to disease progression11. Tau pathology, although varying in 
presentation, has been shown to accumulate in a large number of neurological diseases 
known as tauopathies 150. The variability in age-of-onset for AD and other tauopathies, 
even those caused by bona-fide hereditary mutations, indicates that other 
environmental- and experience-based genetic modifiers are involved in the production 
of pathogenic tau species151,152. One group of age-affected genes that can also 
modulate tau proteostasis is the molecular chaperone family, which includes heat shock 
proteins (Hsps), proteins whose expression increase under conditions of stress153. 
Levels of Hsps diminish with age, and roles for these proteins in neurodegenerative 
disease in relation to the age of onset have been proposed in several models154. In 
particular, the Hsp90 system is of interest as a potential tau “toxifier”9,35. 
We and others have shown that inhibiting Hsp90 can promote tau clearance, 
suggesting that Hsp90 is acting to protect tau in neurons for unknown reasons8,9,155. 
Hsp90 can even enhance tau amyloid formation in vitro, a function unique in 
comparison to other chaperones. Both of these functions of Hsp90 are in contrast to the 
effects of other chaperones that have been shown to enhance tau clearance and 
subvert its amyloidogenesis129. Though several co-chaperones of Hsp90 can influence 
tau stability in cells, this has not been well studied in the brain. For instance, the FK506-
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binding protein 51 kDa (FKBP51/FKBP5) is known to work with Hsp90 to stabilize tau 
and regulate tau phosphorylation35, but the mechanisms and pathological relevance for 
both of these processes are unknown. FKBP51 possesses properties that are similar to 
the cis-trans peptidyl-prolyl isomerase Pin1 that has been reported on extensively156-158; 
however much less is known about the role of FKBP51 in the brain despite its genetic 
association to human psychiatric diseases78. FKBP51 is a pro-folding Hsp90 co-
chaperone that forms a complex with Hsp90 via the tetratricopeptide (TPR) 
domain159,160, a region also found on other Hsp90 co-chaperones, including the carboxyl 
terminus of Hsp70-interacting protein (CHIP/STUB1) and FK506 binding protein 52 
(FKBP52/FKBP4)31,122. However, the TPR co-chaperone with the highest affinity for 
Hsp90 is FKBP51161. Here we investigate how the FKBP51/Hsp90 complex prevents 
tau from clearance, the impact it has on tau pathogenesis, and whether it plays a role in 
disease onset due to age-associated changes in TPR protein levels in the human brain. 
Our findings suggest that environmental or experiential-based epigenetic changes that 
accelerate up-regulation of FKBP51 over time could be a major contributor to the onset 
and pathogenicity of tauopathies, and in particular AD. 
 
3.3 Materials and methods 
3.3.1 Materials 
Antibodies: pT231 (AnaspecTau12 (N-Terminal 2-18; gift from Dr. Lester Binder, 
Northwestern University, Chicago, IL), pT231 (Abcam), NeuN (Millipore), H150 (Santa 
Cruz), T22 (Dr. Rakez Kayed, University of Texas Medical Branch, Galveston, TX), 
Hsp90 (BD Biosciences), GAPDH (Meridian Life Science), FKBP51 (gift from Marc 
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Cox), CHIP (Cell Signaling), FKBP51 (Cell Signaling), and FKBP52 (gift from Marc Cox, 
University of Texas at El Paso, El Paso, TX), Actin (Sigma). 
Plasmids: Hsp90α, CHIP, tau, FKBP51 were generated in our lab using the 
pcDNA3.1 and pCMV6 backbones. 
Human Tissue: Human tissue was obtained from the University of California at Irvine 
MIND Alzheimer’s Disease Research Center (Irvine, California). See Tables 3.1 and 3.2 
for specific details. 
 
3.3.2 Cell culture and transfection 
 HEK293 cells were cultured in Opti-Mem plus media supplemented with 10% 
FBS and 1% Penicillin-Streptomycin (Invitrogen). DNA transfection and lysis procedures 
were followed as described earlier35.  In brief, transfections were performed with 2.5 μl 
Lipofectamine 2000 (Invitrogen) per 1ug DNA was added to serum-free Opti-MEM for 4 
hrs and replaced with serum-containing Opti-MEM for another 44 hrs. For co-IP from 
cellular lysates, cells were harvested in co-IP buffer and pre-cleared with protein G 
(Pierce) and anti-IgG (species) antibody for 1 hr. After passing through a spin column, 
lysates were incubated with Hsp90 antibody for 3 hrs. Protein G was added to the 
mixture and incubated overnight on a shaker at 4ºC. The beads were spun down and 
washed five times. The precipitate was used for Western blots. 
 
3.3.3 Western blot and dot blot analysis 
 Samples extracted from cellular lysates and human brain tissues were analyzed 
by Western blotting using 10% acrylamide gels43. Antibody dilutions were 1:1000 unless 
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otherwise stated. All secondary antibodies were used at 1:1000 (Southern Biotech). 
Blots were developed using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare). 
For dot blots, proteins were applied onto a wet nitrocellulose membrane and dried by 
vacuum.  Once dry, membrane was blocked and developed as described above.  
 
3.3.4 Microarray  
 Postmortem tissue for biochemical analysis was obtained from 7 different ADR 
brain banks by UC Irvine Brain Bank. Microarray analysis was undertaken on 4 brain 
regions (PCG, SFG, HPC and EC) from AD cases (n=26, age 74-95, mean age 85.7 ± 
6.5 yrs), age-matched controls (n=33, age 69-99 yrs, average age 84.2 ± 6.5 yrs) and 
young normal cases (ages 20 to 59; n=22, mean 35.4 ± 10.5 years) using Affymetrix 
arrays 9HgU133 plus 2.0 as described previously 162,163  All subjects were evaluated to 
be cognitively normal or AD based on diagnoses from medical records. mRNA 
expression of each sample was evaluated by gene-chip hybridization as described by 
Cribbs et al 163.  These data are deposited on the MIAME-compliant GEO database 
(Accession number GSE11882). 
 
3.3.5 Pyrosequencing for DNA methylation status 
Tissue from young, aged, and AD samples were homogenized as described 
above.  DNA was extracted using Puregene (Quiagen) chemistry and DNA 
concentration was measured using Qubit 1.0 Fluorometer (Invitrogen).  Methylation 
analysis by bisulfite pyrosequencing was performed as previously described. 164,165. 
Intron 7 was evaluated at six CpG sites: P1_S1_Pos1, P1_S1_Pos2, P1_S2_Pos1, 
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P1_S2_Pos2, P1_S2_Pos3, and P1_S3_Pos1. Intron 2 was analyzed at four CpG sites: 
P4_S1_CG1, P4_S1_CG2, P4_S2_CG1, and P4_S2_CG2. Methylation in the promoter 
region was analyzed for 6 CpG sites: GRE_S1_CG1, GRE_S1_CG2, GRE_S1_CG3, 
GRE_S2_CG1, GRE_S2_CG2, and GRE_S2_CG3. 
 
3.3.6 Statistics 
 To compare 2 groups, a student’s t-test was used.  Groups larger than 2 were 
evaluated using a 1-way ANOVA test. Linear regression was used to show the 
relationship between two variables.  P values below 0.05 were considered significant. 
 
3.4 Results 
3.4.1 Increasing FKBP51 levels with age allows a shift in Hsp90 functionality 
We then sought to determine whether FKBP51 levels could increase with age or 
in disease, perhaps linking FKBP51 to tau pathogenesis. FKBP51 mRNA expression 
was measured via microarray analyses 163 in young (ages 20 to 59; n=22, mean 35.4 ± 
10.5 years) and aged (ages 69 to 99; n=33, mean84.2 ± 8.9 years) non-neurologically 
diseased human brain tissue from the following regions: the postcentral gyrus (PCG), 
entorhinal cortex (EC), hippocampus (HPC), and superior-frontal gyrus (SFG). FKBP51 
expression was significantly increased with age (Figure 3.1A). In fact there was a 3-4 
fold increase in FKBP51 expression in all four regions in the aged samples. Hsp90 
expression levels were unchanged with aging, with the exception of the SFG, which 
showed a significant decrease in expression (Figure 3.1B). Conversely to FKBP51 
expression, FKBP52 and CHIP, two other TPR Hsp90 co-chaperones that could 
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compete with FKBP51 for binding to Hsp90 161, had decreasing trends (Figure 3.1, C-
D), but were not significantly decreased with age in any region measured. Additionally, 
we found that increasing FKBP51 expression levels were significantly correlated with 
age (Figure 3.1E). This was consistent with FKBP51 expression data observed in 
human prefrontal cortex through the BrainCloud program152. Similar results were 
observed at the protein level in the postcentral gyrus by Western blot (Figure 3.2). Thus, 
the aging brain promotes an environment where FKBP51 can dominate the Hsp90 
machine, potentially leading to tau pathogenesis  
Based on these data, we hypothesized that in human tauopathies, increasing 
levels of FKBP51 could allow it to usurp Hsp90 from other co-chaperones with lower 
affinity, causing it to produce toxic tau oligomers rather than sequester tau into more 
benign amyloid fibrils161. Indeed, in cells expressing constant levels of CHIP, an Hsp90 
co-chaperone that can facilitate tau clearance through the proteasome21,47, increasing 
FKBP51 levels were able to displace CHIP from Hsp90 and preserve tau levels (Figure 
3.3). When taken together, these data suggest that elevated FKBP51 can overtake the 
Hsp90 machinery in the aging brain, and alter tau structure in a way that facilitates its 
neurotoxic accumulation.     
 
3.4.2 FKBP5 DNA methylation decreases with aging; a mechanism for its increased 
expression 
It was recently shown that decreases in FKBP5 DNA methylation increase the 
expression of FKBP51 164.  To see if this was the mechanism leading to the significantly 
increased FKBP51 expression found in the aged brain, methylation analysis using 
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pyrosequencing was performed on DNA from PCG brain tissue of aging non-demented 
samples (N=6) on multiple CpG sites in functional glucocorticoid response elements in 
Intron 7, Intron 2, and the promoter (Figure 3.4, A-C) of FKBP591. While Intron 2 showed 
no significant linear decrease in methylation with aging, Intron 7 and the promoter had 
seven CpG sites for which DNA methylation was significantly decreased with aging. 
Significant demethylation in Intron 7 was found at five CpG positions (Figure 3.4A).  
Methylation was significantly decreased in the promoter in two locations (Figure 3.4B). 
These age-associated decreases in DNA methylation in specific regulatory elements 
could explain why FKBP51 expression is progressively increased with age (Figure 
3.1E). 
 
3.4.3 FKBP5 expression is further increased in the Alzheimer’s brain, perhaps through 
altered FKBP5 DNA methylation 
Given the role of FKBP51 on tau accumulation and its pathogenicity, we 
examined whether FKBP51 levels were elevated further in Alzheimer’s disease brain 
compared to normal age matched controls. FKBP51 mRNA expression was measured 
using microarray analyses from the PCG, EC, HPC, and SFG of AD individual 
diagnosed brain samples (n= 26, 74-95 yrs old; mean age 85.7 ± 6.5) and age-matched 
control samples (n=33, age 69-99 yrs, average age 84.2 ± 6.5 yrs)163. FKBP51 
expression was significantly increased in AD diagnosed cases compared to age 
matched controls, while the levels of Hsp90 and other TPR containing proteins were 
unchanged with disease state (Figure 3.5A).  FKBP51 expression was much higher in 
younger individuals with AD (aged 70-80), but level of FKBP51 in older individuals with 
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AD (>80) were indistinguishable from older non-demented individuals (Figure 3.5B). 
This suggests that AD accelerates age-associated FKBP51 up-regulation. Protein levels 
were also evaluated in a sub-set of these cases using medial temporal gyrus tissue. 
FKBP51 expression was increased in the AD diagnosed cases, compared to the age-
matched cognitively normal cases (Figure 3.6, A-B). Hsp90 levels appeared unchanged, 
while the levels of FKBP52 and CHIP trended toward a decrease in AD cases. In 
addition, those samples with higher tau levels, regardless of disease diagnosis, also 
had overall higher FKBP51 levels, further supporting a link between FKBP51 and tau 
accumulation. 
 Based on these results, we speculated that increasing FKBP51 levels might 
correlate with disease progression or disease onset. To assess this possibility, 
correlation analyses were performed based on Braak staging. We chose Braak staging 
as the most unbiased measure for disease progression. Indeed, increased FKBP51 
levels were significantly correlated with increased Braak staging, suggesting that 
FKBP51 may have a role in AD progression (Figure 3.7).  In this way, FKBP51 may play 
a role in accelerating disease onset and progression by facilitating the production and 
accumulation of toxic tau, leading to Alzheimer’s disease and expediting its 
pathogenesis.  
 To evaluate the role of AD on FKBP5 DNA methylation the same pyrosequencing 
analyses as described above were performed on brain tissue from the MTG (medial 
temporal gyrus) of AD (n=10) and aged-matched controls (n=5). There was a significant 
decrease in methylation at 3 CpG sites; one in Intron 7 (Figure 3.8A) and two in the 
promoter (Figure 3.8B). There was only one position where DNA methylation was 
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increased in the AD population (Figure 3.8C).   There was also a decreasing trend of 
overall FKBP5 methylation in intron 7 as well as the promoter areas at every tested 
CpG of AD diagnosed samples compared to non-demented aged matched controls 
(Figure 3.9).   
 
3.5 Discussion 
We show that FKBP5 methylation is reduced both with age and in disease, which 
could be one factor leading to increased FKBP51 expression90,164,166. FKBP5 
methylation and FKBP51 expression appear to be inversely proportional over time. 
Therefore it is certainly conceivable that age could combine with other factors such as 
stress or genetic variation to increase FKBP51 expression to detrimentally high levels. 
We found that FKBP51 levels were further enhanced in the AD brain compared to age-
matched controls, possibly resulting from FKBP5 demethylation in these functional 
regulatory elements as shown previously 164. In fact, the progressive increases in 
FKBP51 levels correlated with Braak staging in the entire sample population as well as 
the non-demented aging sub-population alone. Additionally, since the FKBP5 gene is 
responsive to stress hormone164, the levels of which increase in AD167, FKBP51 could 
be exploited as a novel biomarker to compliment other such molecules for evaluating 
AD risk.  
Based on these findings, we predict that people predisposed to increased levels of 
FKBP51 could display a higher risk for AD onset and possibly a more rapid progression 
of the disease. On the other hand, it is possible that the pathogenic processes that 
manifest in AD facilitate increased FKBP51 expression as well, which could also explain 
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why FKBP51 levels are further increased in AD compared to age-matched controls. 
Either scenario would likely create a vicious cycle in the brain that contributes to 
disease progression.  
Overall, this study shows that a significant increase in FKBP51 levels in the aged 
and Alzheimer’s brain could promote an environment that preserves toxic tau oligomers. 
We show that FKBP51 coordinates with the Hsp90 machinery to alter tau structure, 
block its degradation and promote abnormal oligomer formation. This strongly 
implicates FKBP51 as a therapeutic target for AD and other tauopathies. These data 
ultimately shed light on the nature of tau accumulation and support a new body of 
research suggesting that chaperone proteins impede rather than aid in the 
pathogenesis of these diseases.  
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Table 3.1. Human sample data for tissue used in Figure 3.2.  
 
 
 
 
 
ApoE indicates allelic variant.
Age Sex ApoE 
21 M 2-3 
36 F 3-4 
42 M 3-4 
74 F 2-3 
85 M 3-3 
95 M 2-3 
 
 
60 
 
Table 3.2. Human sample data for tissue used in Figure 3.6.  
Age Sex PMI ApoE NPDx1 Tangle 
Stage 
Plaque Stage 
81 M 2.87 n/a Alzheimer's disease Stage 6 Stage B 
90 F 6.58 3/3 Alzheimer's disease Stage 6 Stage C 
90 M 4.17 3/3 Alzheimer's disease Stage 6 Stage C 
88 F 4.5 3/3 Alzheimer's disease Stage 5 Stage C 
77 M 5.67 2/4 Alzheimer's disease Stage 6 Stage C 
82 F 4.58 3/4 Alzheimer's disease Stage 6 Stage C 
87 M 6.17 3/4 Alzheimer's disease Stage 5 Stage A 
96 F 4.5 3/3 Alzheimer's disease Stage 6 Stage C 
86 M 4.2 3/4 Alzheimer's disease Stage 5 Stage C 
79 F 5 3/3 Alzheimer's disease Stage 6 Stage C 
94 M 3.87 3/3 Normal (Mild Braak Changes) Stage 1 None 
97 M 4 3/3 Normal (Mild Braak Changes) Stage 2 Stage B 
91 F 3.8 3/3 Normal (Mild Braak Changes) Stage 2 Stage A 
96 M 3.58 2/3 Normal (Mild Braak Changes) Stage 2 None 
83 M 1.8 3/3 Normal (Mild Braak Changes) Stage 2 None 
PMI indicates post mortem interval. ApoE indicates allelic variant. NPD indicates 
neuropathological determination. Tangle stage is used for Braak staging.  
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Figure 3.1. FKBP5 expression increases age-dependently in many brain regions.  
(A) FKBP51, (B) Hsp90, (C) FKBP52, and (D) CHIP mRNA expression from young (20-
59) and aged (69-99) samples from the post central gyrus (PCG), superior frontal gyrus 
(SFG), hippocampus (HPC), and entorhinal cortex (EC). *p<0.05, **p<0.01, ***p<0.001 
(E) The average FKBP5 mRNA expression from all 4 regions for each sample was 
plotted against age. P < 0.0001; r = 0.4916. 
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Figure 3.2. FKBP51 levles increase with age in the human brain. (A) Human brain 
homogenates from the PCG of 4 males (ages 21, 42, 85, and 95 years) were analyzed 
by Western blot by FKBP51, Hsp90, FKBP52, CHIP, and GAPDH antibodies. (B) 
Quantification of protein levels with aging from multiple blots. FKBP51, P = 0.0765, r = 
0.8528; Hsp90, P = 0.394, r = 0.3672; FKBP51, P = 0.9632, r = 0.001352; CHIP, P = 
0.0269, r = 0.9469.   
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Figure 3.3. Increased FKBP51 alters Hsp90 complexes. Hek cells transfected with 
Tau, FKBP51, Hsp90, and CHIP, respectively, were harvested after 48 hours. Following 
mouse anti-Hsp90 antibody immunoprecipitation, samples were analyzed by Western 
blot for FKBP51, CHIP, Hsp90, Tau 12 (total tau), and GAPDH antibodies, respectively.   
 
 
64 
 
Figure 3.4. FKBP5 DNA demethylation with aging. Average FKBP5 methylation 
analysis of human DNA samples from the PCG of individuals aged 21, 36, 42, 74, 85, 
95 years were performed on multiple CpG sites in (A) intron 7, (B) promoter, and (C) 
intron 2. Significant demethylation in intron 7 was found at P1_S1_Pos2 (P = 0.0012, r = 
0.6506), P1_S2_Pos1 (P = 0.0007, r = 0.9585), P1_S2_Pos2 (P = 0.0039, r = 0.9002), 
P1_S2_Pos3 (P = 0.0039, r = 0.9002), and P1_S2_Pos3 (P = 0.0240, r = 0.7583). 
Methylation was significantly decreased in the promoter at GRE_S1_CG1 (P = 
0.0327, r = 0.7199) and GRE3_S1_CG3 (P = 0.0216, r = 0.7698). 
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Figure 3.5. FKBP5 mRNA increases in AD samples. (A) Average mRNA expression 
(± SEM) from the SFG, PCG, EC, and HPC of AD and age-matched (69–99 years) 
samples. *P = 0.0306. (B) FKBP5 expression correlation with aging in AD and age-
matched samples.  
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Figure 3.6. FKBP51 levels increase in AD samples, leading to chaperone 
imbalance. (A) A representative image from Western blot analysis of the medial 
temporal gyri of 4 male aged and AD samples. Blots were probed with FKBP51, Hsp90, 
CHIP, FKBP52, H150 (total tau), pT231, and actin antibodies. (B) Quantification of total 
levels, as they correlate to FKBP51 levels. P = 0.0203, pT231; P = 0.0045, H150 (total 
tau); P = 0.0251, T22.   
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Figure 3.7. Braak staging correlates with FKBP5 expression.  Linear regression 
of FKBP5 expression levels with Braak staging in aged (69-99 years) individuals. The 
average mRNA expression from all 4 regions for each sample, including demented 
(Blue) and non-demented (green) individuals, was plotted against Braak stage. P = 
0.0036; r = 0.1774.  
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Figure 3.8. FKBP5 methylation is decreased in AD brain. Average methylation (± 
SEM) analysis of human DNA from the medial temporal gyrus of AD and age-matched 
samples from multiple CpG sites from (A) intron 7, (B) the promoter, and (C) intron 2 
of FKBP5. Significant demethylation in AD genotype was found in intron 7 at 
P1_S3_Pos1 (*P = 0.0243) and in the promoter at GRE_S1_CG2 (#P = 0.0105) and 
GRE3_S2_CG3 (##P = 0.0424). Significant methylation was found in intron 2 at 
P4_S1_CG1 (†P = 0.0244). 
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Figure 3.9. Methylation analysis in an aging and AD population. Average human 
FKBP5 DNA methylation of the medial temporal gyrus from multiple CpG sites from (A) 
Intron 7, (B) Intron 2, and the (C) Promoter in AD and aged samples by age. 
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CHAPTER FOUR: 
THE GENERATION AND CHARACTERIZATION OF rTgFKBP5 MICE 
 
4.1 Abstract 
FK506-binding protein 51 kDa (FKBP51), encoded by FKPB5, is an immunophilin 
with peptidyl-prolyl isomerase (PPIase) activity. More importantly, FKBP51 contains a 
tetratricopeptide repeat (TPR) domain, a motif which can directly bind to Heat shock 
protein 90 kDa (Hsp90). We previously showed that viral overexpression of FKBP51 
works with Hsp90 to preserve toxic, oligomeric tau. This microtubule stabilizing protein 
is known to aberrantly accumulate in a group of neurological diseases known as 
tauopathies, the most common being Alzheimer’s disease.  Mice ablated for fkbp5 had 
lower endogenous tau levels.  However, there is not a transgenic model that over-
expresses FKBP51 showing the opposite phenotype. For drug discovery efforts to move 
forward towards compounds or biological agents that can deplete FKBP51, we have 
generated a tetracycline (tet)-regulatable FKBP5 transgenic mouse model. This mouse 
model, rTgFKBP5, which shows clear upregulation of FKBP51, will serve as the first-in-
class platform to test whether strategies aimed at depleting FKBP51 to identify 
treatments directed towards Hsp90/tau complexes. 
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4.2 Introduction 
 
FK506 Binding Protein 5 encodes a large molecular weight immunophilin, 
FKBP51, known most for regulating in hormone receptor64.  There are two important 
domains in FKBP51, a tetratricopeptide repeat (TPR) domain for direct Heat shock 
protein (Hsp) 90 kDa binding and a peptidyl-prolyl-cis/trans isomerase (PPIase) domain 
for isomerase activity and high-affinity binding to immunosuppressive drugs like FK506 
and rapamycin63.  
The FKBP5 gene has been associated with many psychiatric disorders84. Single 
nucleotide polymorphisms (SNPs) have recently been identified to be linked with higher 
levels of FKBP5191.  These SNPs have also been linked to trauma during childhood 
leading posttraumatic stress disorder (PTSD)72, other links include greater risk for 
depression168, depressive episodes169, mood disorders170, suicide171 and anxiety 172. It 
has also been shown to play a role in obesity 173-175 and levels of expression have been 
shown to correlate with stages of certain cancers176,177. FKBP51 is age-dependently 
expressed13,35,89, which is correlated with an increased number and length of psychiatric 
episodes in the elderly population. Yang et. al. recently showed overexpressing 
FKBP51 using an AAV viral vector caused mice fed a high-fat diet gained more weight 
than their control littermates, and this weight gain was associated with decreased 
glucose tolerance coupled with high corticosterone levels173.   
FKBP51 has been well characterized in regards to the stress hormone system 
that controls the hypothalamic/pituitary/adrenal (HPA) axis71. FKBP51 serves to reduce 
the activation of the glucocorticoid receptor (GR) by cortisol, the primary stress hormone 
in humans178. This inhibition results in diminished movement of GR into the nucleus, 
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which changes the rate of transcription of many genes, ultimately allows us to cope with 
acute stress179. During normal acute stress, GR activation attenuates the HPA-axis 
stress response through a feedback inhibition cycle. However, too much FKBP51 can 
slow this process down, allowing cortisol levels to accumulate and stimulate other 
untoward physiological effects180. Inversely, the consequence of prolonged activation of 
the HPA-axis has many negative outcomes, most overlapping with those found in risk 
SNP carriers.  These outcomes include weight gain181, depression182, suicidal 
tendencies183, PTSD184,185, psychosis186, and even altered immune function 187. In 
addition to these psychopathologies, our group recently ascribed a role for FKBP51 in 
tau biology13,35. 
In our first FKBP51 focused study, we found that tau metabolism was drastically 
altered in the presence of very high or low levels of FKBP5135. In other words, in 
circumstances of FKBP51 knock-down tau levels were significantly reduced, and in the 
presence of FKBP51 overexpression tau levels were preserved. In our follow-up study, 
we found that FKBP51 levels increase dramatically with aging and correlate to 
increased tau accumulation in the human brain13. We were able to characterize this 
preserved tau as a phosphorylated, oligomeric, and toxic species. Thus, FKBP51 may 
prove to be an important therapeutic target for drugs aimed at altering tau metabolism. 
We and others have employed mice that do not produce any FKBP51 to test 
whether deletion of this important gene could reduce susceptibility to trauma-induced 
psychopathologies. In behavioral paradigms similar to extreme physical conditioning 
and situational hopelessness in humans, mice lacking FKBP5 (FKBP5 -/-) showed more 
resiliency compared to wild-type littermates89,188,189. Induction of corticosterone levels 
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(the rodent equivalent of human cortisol) was significantly attenuated following stress in 
these FKBP5-/- mice. In this way, the lack of FKBP51 was enhancing the brain’s 
responsiveness to and/or production of corticosterone. Importantly, the mice lacking 
FKBP51 were otherwise behaviorally intact: They had no memory or motor deficits and 
there were no abnormal gross pathologies observed. Moreover, we have additional data 
showing that these mice have normal blood glucose levels, white blood cell counts and 
body mass despite these alterations in psychological resiliency and corticosterone 
production. This suggests that FKBP51 is most important for the brain's response to 
cortisol and other deleterious peripheral consequences associated with cortisol over-
production may not occur. While knockout mice provide the proof-of-concept that this is 
a feasible strategy, there has not been a transgenic model that over-expresses FKBP51 
until now. For drug discovery efforts to move forward towards compounds or biological 
agents that can deplete FKBP51, a transgenic model that recapitulates stress-induced 
depressive-like phenotypes due to FKBP51 over-expression is needed.   
We have developed a transgenic mouse over-expressing FK506 Binding Protein 
51 (FKBP51) selectively in the brain, which will be a highly valuable tool for future drug 
discovery efforts aimed at altering tau metabolism, and also for strategies for improving 
psychological resiliency after trauma. Exposure to traumatic events can lead to stress-
induced psychological disorders including depression, suicide, bipolar disorder, 
peritraumatic dissociation, aggression and post-traumatic stress disorder (PTSD). This 
mouse model may be beneficial in look for therapeutics for each of these 
psychopathologies. Naturally-occurring genetic variants in the gene encoding FKBP51 
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(FKBP5) increase susceptibility to these disorders often by increasing FKBP51 
levels72,75,78,171,190-195. 
The creation of this mouse model overexpressing human FKBP51 will be 
beneficial in measuring the consequences of changes in FKBP51 expression with aging 
and also the higher levels found associated with SNPs.  It would have implication in not 
only tau research but also depression, stress, cancer, and obesity research. The only 
model of increased FKBP51 expression reported is the naturally occurring increased 
levels found in New World monkeys known to have an increased resistance to 
glucocorticoids.  There are great limitations to studying no-human primates, and a small 
rodent model would be better suited.   
 
4.3 Materials and methods 
4.3.1 Ethics statement 
All studies were carried out following the guidelines set by the University of South 
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AALAC) regulations.   
 
4.3.2 Construction of the tet-controlled FKBP51 vector 
Transgenic construct was generated by cloning a human FKBP51 cDNA a Tet-
Op-mp1pA vector. A PmeI site was added into the mp1 pA vector (gift from Noreen 
Luetteke) and ligation of the FKBP51 cDNA in the vector with ClaI and EcoRV. 
Successful ligation was confirmed using a digestion to identify FKBP51 via gel 
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electrophoresis.  This construct was then subcloned into a pBT378 (gift from Noreen 
Luetteke) vector using PmeI and NotI restriction sites and then confirmed by gel 
electrophoresis. 
  
4.3.3 Cell culture 
  
 HEK293 cells were grown in Opti-MEM with 10% FBS and 1% Penicillin-
Streptomycin (Invitrogen). DNA transfections were performed using 2.5 µ Lipofectamine 
2000 (Invitrogen) in serum-free Opti-MEM, following cells were incubated for 24 or 48 
hours as indicated before harvest. Cells were harvested in MPER buffer supplemented 
with protease inhibitor, phosphatase inhibitors and PMSF, incubated on ice for 20 
minutes, centrifuged, and supernatants were used for Western blotting. 
 
 
4.3.4 Generation of rTgFKBP5 mice 
 The final transgenic plasmid was microinjected combined with ΦC31 integrase 
mRNA (Invitrogen) into isolated fertilized mouse (FVB/N) oocytes which have the 
matching attP integrase sites.  Successfully injected eggs were re-implanted into 
pseudo-pregnant females. Micro injections and founder mice were generated in the 
Stanford Transgenic Research Center and shipped to the University of South Florida for 
genotyping and characterization. 
 
4.3.5 Genotyping of bigenic mice 
 Mouse genotypes were determined by PCR followed by DNA electrophoresis. 
Briefly, ear clips were digested overnight and then amplified by PCR using HotStarTaq 
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Plus Master Mix (Qiagen), betaine and dye with in two separate reactions.  The first 
amplification was amplified by forward and reverser primers for the human FKBP5 gene 
(F, 5’GTGTACGGTGGGAGGCCTAT3’, and R, 5’GTCCCATGCCTTGATGACTT3’) and 
housekeeping gene T-cell receptor delta chain (Tcrd) (F, 5’-
CAAATGTTGCTTGTCTGGTG-3’, and R, 5’-GTCAGTCGAGTGCACAGTTT-3’) to 
confirm presence of tissue.  Genomic DNA was amplified by PCR in a thermocycler 
(Eppendorf) using the following conditions: 95°C for 15 minutes; 30 cycles of 95°C for 
15 seconds, 68°C for 30 seconds and 72°C for 45 seconds; followed by 11 cycles of 
95°C for 15 seconds and 50°C for 30 seconds, and 72°C for 45 seconds; and then 10 
minutes of 72°C. The second amplification was amplified by forward and reverser 
primers for the CamKIIα tTA (F, 5’CGCTGTGGGGCATTTTACTTT3’, and R, 5’-
CATGTCCAGATCGAAATGGTC-3’) and housekeeping gene Tcrd.  Genomic DNA was 
amplified by PCR in a thermocycler (Eppendorf) using the following conditions: 95°C for 
15 minutes, and 20 cycles of 95°C for 15 seconds, 68°C for 30 seconds and 72°C for 45 
seconds; followed by 10 cycles of 95°C for 15 seconds, 50°C for 30 seconds, and 72°C 
for 45 seconds; and then 10 minutes of 72°C. PCR product was then run on a Qiaxcel 
(Qiagen) and also by gel electrophoresis on a 2% agarose gel for analysis.  
 
4.3.6 Tissue collection 
At sacrifice, mice were weighed and overdosed with a pentobarbital solution and 
transcardially perfused with 0.9% saline solution until brains were clear of blood.  Brains 
were carefully removed and dissected into hemispheres.  The left hemisphere was 
immediately submerged into fresh 4% paraformaldehyde solution for 24 hours and 
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stored in DPBS supplemented with azide solution until sectioned.  The right hemisphere 
was subdivided into anterior cortex, posterior cortex, hippocampus, striatum, cerebellum 
and the rest of the brain, which was quickly put into labelled cryotubes, capped, and 
flash frozen using dry ice and ethanol.  
 
4.3.7 Biochemical analysis of tissue  
Brain bits used for biochemical analysis were kept frozen when weighed and 
homogenized using a tissue homogenizer (IKA) for 30 seconds in 50mM Tris Base, 
274mM NaCl and 5mM KCl at pH 8.0, supplemented with protease inhibitor for tissue 
(Sigma), phosphatase inhibitors and PMSF. This was followed by 20 pulses of 
sonication. Samples were then kept on ice for 15 minutes and centrifuged at 13,000 x g 
for 15 minutes. Supernatants were transferred to a new tube and used for Western 
blotting 
 
4.3.8 Western blotting 
BCA protein estimation was performed on tissue and cell lysates used for 
Western blots.  Samples were denatured and run on 10% acrylamide gels. All primary 
and secondary antibodies were used at 1:1000 dilutions.  Blots were developed on a 
LAS-4000 imager (GE Healthcare) using ECL (Pierce). 
 
4.3.9 Immunohistochemical analysis of tissue 
 Fixed tissue was submerged in 10%, 20% and 30% sucrose for 24 hours.  Once 
the brains acclimated to the 30% sucrose, tissue was sectioned 25µM think on a 
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freezing stage using a sliding microtome. Sectioned tissue was submerged in DPBS 
supplemented with 0.2% sodium azide.  
 
4.4 Results and discussion 
4.4.1 Generation of the rTgFKBP5 mice 
The responder transgene (Figure 4.1) was created by cloning a human FKBP51 
cDNA into a tetracycline-inducible vector called Tet-Op-mp1pA. This was achieved by 
the addition of a PmeI site into the mp1 pA vector (gift from Noreen Luetteke) via 
mutagenesis. Second, we digested the vector with ClaI and EcoRV to ligate in FKBP51.  
This vector is a pBluescript II SK phagemid that contains bacteria derived tetracycline-
responsive promoter element (TRE). This element is comprised of the Tet operon 
(TetO), seven identical repeats of a 19 bp tet operator sequence, followed by a human 
derived minimum CMV (cytomegalovirus) promoter. This TetO At the 3’ end of the 
vector a 0.5kb fragment comprised of a mouse protamine-1 gene intron (Mp1) and a 
polyadenylation (pA) sequence located downstream of the inserted FKBP51 stabilize 
the cDNA196. The Tet-op-mP1 was used to make a successful tetracycline regulatable 
epidermal growth factor receptor (EGFR) transgenic mouse model197. To prevent 
transcription interference with the transgene, a 2.4kb fragment containing two copies of 
the chicken beta-globin insulator (cHS4) was subcloned upstream of the TetO 
sequences. This insulator has been shown to dramatically increase the expression of 
the subsequent cDNA sequence198 and protects against DNA methylation199. The TetO-
FKBP51 transgene will be cut out using the added PmeI and existing NotI restriction 
sites and subcloned into a vector called pBT378 (gift from Noreen Luetteke) in between 
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two bacteriophage derived attB sites that are recognized by the phage ΦC31 
integrase200,201. The flanking by attB sites allow for a high efficiency single-copy 
insertion of the gene into the Hip11 locus on chromosome11202. PhiC31 intragese will 
be used to direct integrations into the attP-tagged permissive genomic site for reliable 
expression as shown in Figure 4.2.  
The effectiveness and tet-responsiveness of the plasmid were evaluated in cells 
stably expressing the tet-repressor (Figure 4.3). HEK cells were transfected with 
indicated amounts of FKBP51 responder (51Rspd; Figure 4.3A), and tet-repressor (TR; 
Figure 4.3B) or tet-transactivator (tTA; Figure 4.3C) for 24 hours. Cells were then 
treated with indicated concentrations of tetracycline for 48 hours and lysates were 
analyzed by Western blot for FKBP51 and GAPDH. The construct behaves as expected 
in culture, in other words the FKBP51 responder (Figure 4.3A) dose dependently 
increases the levels of FKBP51. The Tet-repressor (Figure 4.3B) blocks expression of 
FKPB51, which then can be rescued dose dependently by tetracycline, mimicking what 
would happen when crossing a mouse made with this construct to rtTa mice.  The tet-
transactivator (Figure 4.3C) drives FKBP51 expression, which can then be shut off by 
treatment with tetracycline, demonstrating what would happen when crossing a mouse 
with this vector with a tTa mouse (Figure 4.4). Following confirmation of the vector, 
pronuclear injections were performed by Stanford University and founders were 
received and genotyped. Four of the twenty-five mice were positive for the responder 
gene.   
We then crossed mice expressing the responder transgene onto tetracycline 
activator line following the tTA (tetracycline-controlled transactivator) system as first 
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described by Gossen and colleagues203.  The tTA is comprised of an Escherichia coli 
derived Tet repressor (TetR) DNA binding sequence from the transposon Tn10 fused to 
a VP16 protein made from Herpes Simplex Virus. In the heterozygous offspring, the 
TetR will bind to the tetO operator sequence and drive transcription.  The addition of 
tetracycline will cause the repressor to disassociate from the Tet operon preventing 
TRE driven transcription (Figure 4.5) 204. To drive the expression of FKBP51 in forebrain 
neurons, we crossed the mice with a calcium/calmodulin-dependent protein kinase II 
alpha (CamKIIα) tTA line. This line contains an activator transgene made of a tet-off 
open reading frame followed by a Ca2+/calmodulin dependent protein kinase II promoter 
element205. This promoter drives high expression primarily in the grey matter of the 
forebrain neurons; primarily in the forebrain and hippocampus205,206.  
 
4.4.2 Analysis of FKBP51 overexpression 
In order to confirm over overexpression of FKBP51, we analyzed tissue 
homogenates from one month rTgFKBP5 mice and non-transgenic littermates by 
Western blot and staining. Western blot analysis of the anterior cortex showed clear up-
regulation of FKBP51 (Figure 4.6) compared to wild-type littermates. We then looked at 
the FKBP51 levels in discrete regions of the brain in a 4 month rTg4510 mouse (Figure 
4.7) including the hippocampus (HPC), striatum (STR), anterior cortex (ACX), posterior 
cortex (PCX), the rest of the brain not subdivided (ROB) and the cerebellum (CER). We 
found that expression was highest in the hippocampus, followed by the posterior cortex, 
then the anterior cortex and striatum.  There was mild over expression in the “rest of 
brain” bit.  This is most likely not the level of expression in that entire brain region, but 
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an average of regions of high expression and low expressing mixed together, further 
analysis of tissue need to be done to look at levels throughout the mid brain.  The 
cerebellum showed no detectable overexpression of FKBP51, as expected from the 
expression pattern of the CamKIIα promoter. To look at the expression pattern in the 
hippocampus and the cortex of these mice we stained for FKBP51 (Figure 4.8).  This 
staining confirmed high FKBP51 overexpression throughout the hippocampus and 
anterior cortex of the rTgFKBP5 mouse model. 
This new mouse model, which is the first to over-express FKBP51, will allow for 
an extensive characterization of the behavioral and biochemical effects of excess 
FKBP51. Since we designed the mice with a tet-regulatable system, we can alter this 
system depending on the chosen mate. Depending on the mate selected the expression 
of FKBP51 can either be constant over-expression (Tet-Off) or a drug dependent 
overexpression (Tet-On).  The expression locations can be selected by using different 
promoters on the tet-expressing mice. This system will allow the study of sudden higher 
expression of this protein in discrete and specific tissue or high overexpression 
ubiquitously throughout the mouse. This novel model will also serve as a testing 
platform for new therapeutics which target FKBP51 for the treatment of tauopathies and 
other psychopathologies. 
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Figure 4.1 Key elements in the vector. The inserted gene will be tet-regulatable by 
the Tet-operon after crossing with a mouse expressing a tet-transactivator (tTA) or a tet-
repressor (rtTA). Continual minimal expression will be driven by the minimal 
cytomegalovirus (CMV) promoter just before the FKBP5 human gene.  This expression 
will be stabilized by an Mp1 polyadenylation tail. 
 
 
 
Figure 4.2 Schematic depicting the detailed transgene inserted to generate 
rTgFKBP5 mice. This tet-regulatable vector will be specifically inserted by the flanking 
attB sites via a PhiC31 integrase into the mouse genome in chromosome 11.  The 
inserted DNA will have stable expression due to the upstream cHS4 insulator and 
downstream Mp1 polyA tail. The tet-operon repeats allow a tet-transactivator/repressor 
regulation of the minimally expressed, due to the minimal CMV promoter, human 
FKBP51. 
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Figure 4.3. The engineered tet-responsive FKBP5 construct behaves as expected 
in HEK cells. HEK cells were transfected with indicated amounts of FKBP5 responder 
(51Rspd; A) and Tet-repressor (TR; B) or tet-transactivator (tTA; C) for 24 hours. Cells 
were then treated with indicated concentrations of tetracycline for 48 hours and lysates 
were analyzed by Western blot for FKBP5 and GAPDH. 
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Figure 4.4. tTA regulation schematic. This schematic depicts the Tet-off system in 
which the tet-transactivator (tTA) binds to the tet-response element (TRE/tet-operon) 
and drives high expression of FKBP51.  Upon treatment with doxycycline (Dox), the tTA 
is bound by Dox, preventing activation of the TRE and halting subsequent upregulation 
of the FKBP5 gene. 
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Figure 4.5. Making bigenic rTgFKBP5 mice. Tet-transactivator (tTA) mice controlled 
by the CamKIIα promoter were crossed with mice expressing FKBP51 under control of 
the tet-responder element (TRE). These Tet-off mice will overexpress human FKBP51 
in CamKIIα expressing cells.  FKBP51 overexpression is shut off by treatment with 
doxycycline (Dox). 
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Figure 4.6 FKBP51 levels in the rTgFKBP5 mice. Western blot analysis of FKBP51 
levels in the anterior cortex of rTgFKBP5 and non-transgenic mice. 
 
 
 
 
Figure 4.7 FKBP51 levels in various brain regions of rTgFKBP5 mice. Western blot 
analysis of FKBP51 levels in the hippocampus (HPC), striatum (STR), anterior cortex 
(ACX), posterior cortex (PCX), the rest of the brain not subdivided (ROB) and the 
cerebellum (CER). 
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Figure 4.8. Distribution of FKBP51 overexpression in rTgFKBP5 mice. Fluorescent 
staining was performed to detect FKBP51 in the brains of non-transgenic and 
rTgFKBP51 mice. Images of the hippocampus (CA1, CA3, dentate gyrus) and anterior 
cortex (CTX) are shown. Scale bar represents 200 um.   
 
 
88 
 
 
 
 
CHAPTER FIVE: 
FINAL CONSIDERATIONS 
 
 This study validates Hsp90 co-chaperone, FKBP51, as an important regulator of 
tau metabolism.  The major findings of this study demonstrate that FKBP51 coordinates 
with Hsp90 to preserve tau in a state that is 1) unable to be degraded by the 20S 
proteasome, 2) low in β-sheet structure, 3) highly phosphorylated at threonine 231, 4) 
oligomeric, and 5) neurotoxic.  We have clearly shown that FKBP51 levels in the human 
brain increase with aging. Aging is the greatest major risk factor for Alzheimer’s disease 
(AD) and many tauopathies207. This work, combined with that of the Rein lab161, shows 
that FKBP51 can usurp Hsp90 from other co-chaperones to promote tau accumulation. 
This study supports the idea of identifying drugs which target Hsp90 through FKBP51 
modulation as a therapeutic option for the treatment of AD and other tauopathies. 
Another key result of this study is the generation of a novel, tet-regulatable FKBP51 
overexpressing mouse model.  This model can now be used to test therapeutics, as 
they are identified, which target FKBP51 for their effectivenes in vivo.  
It has been known for quite some time that modulating Hsp90 can affect the 
degradation of tau9. Hsp90 inhibitors, as described in Chapter 1, have repeatedly shown 
that the inhibition of the Hsp90 ATPase leads to the degradation of tau. Many of these 
small molecule inhibitors have now entered or completed clinical trials (Table 1.2) 
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primarily for the treatment of several forms of cancer208-210.  Many of these clinical trials 
are still in progress, but a number of them have failed due to toxicity and 
bioavailability208. Additionally, since many Hsp90 inhibitors are developed for the 
purpose of treating cancers which are found in the periphery210, so blood-brain barrier 
(BBB) permeability is not necessary considered in the design.  In fact, Hsp90 inhibitors 
which cannot cross the BBB may be optimal for the treatment of peripheral diseases to 
limit off-target central effects.  However, for the treatment of AD and other tauopathies, 
BBB permeability is necessary for a peripheral route of treatment, which is preferred. 
While treating tauopathies through Hsp90 inhibition is still promising based on steady 
advancements in the development of small-molecule inhibitors. However, any inhibitor 
targeting Hsp90 is still likely to have many off target effects, given the many roles of this 
major chaperone3. This study supports the idea of taking a more targeted approach in 
regulating the functions of Hsp90 through FKBP51, a co-chaperone with more limited 
functions in the cell, especially given the lack of a negative phenotype in FKBP5-/- 
mice89. 
This approach has clear limitations, since there are currently no drugs available 
which specifically target FKBP51, over its homolog FKBP52. However, with the creation 
of mice overexpressing FKBP51, in vivo testing will now be expedited once drugs are 
identified. It is unlikely that drugs designed to inhibit the PPIase domain of FKBP51 will 
have potent effects on tau pathology, since tau levels were still preserved following 
overexpression of a PPIase null mutant of FKBP5135.  Further studies on the effects of 
the PPIase domain of FKBP51 need to be performed to confirm this.  It is conceivable 
that the phosphatase activities of FKBP51 dephosphorylate tau in specific sites which 
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lead to toxic oligomerization instead of silver positive tangles. Previous work from our 
lab showed that using a PPIase null FKBP51, with a F130A mutation, still led to 
accumulation of similar tau species as with overexpression of wild-type FKBP51 with a 
few exceptions 35.  The PPIase null FKBP51 showed further increased phosphorylation 
of tau at pS396/pS404, pS212, and pT231 compared to wild-type FKBP51, while both 
showed substantially higher tau accumulation and phosphorylation than the control 
without FKBP51 overexpression. In addition to these sites, tau was highly 
phosphorylated at pS262/S356, the main site of MARK2 phosphorylation, which was not 
detectable with wild-type FKBP51 treatment. More studies with PPIase mutants of 
FKBP51 are needed in order to fully understand the role of the PPIase domain in 
regulating tau. 
If the PPIase domain proves to have little effect on tau biology, drugs will need to 
be identified or synthesized to decrease FKBP51 levels, either by increased 
degradation or decreased transcription to have a higher potential of affecting tau 
metabolism.  Drugs which modulate the FKBP51/Hsp90 complex or the binding of 
FKPB51 and Hsp90 also have potential to be therapeutically active in the treatment of 
AD. The development of drugs which target FKBP51 in any of these ways may also 
prove to be effective in treating the deleterious effects of FKBP51 found in many 
psychopathologies and cancers. The rTgFKBP5 mouse model, generated in this study, 
will serve as therapeutic platform to test these drugs in vivo. 
This study was inconclusive in the ability of FKBP51 to decrease age of onset of 
AD.  This was a limitation due to the age of onset being unavailable from the samples 
used for the mRNA studies. We would predict that age of onset of AD is accelerated by 
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increased FKBP51 levels, based on the correlation of FKBP51 to an increase in many 
disease relevant types of tau shown in Figure 3.613. 
FKBP51 SNPs, although implicated to increase risk for many diseases84,211, has 
not been linked to AD or other tauopathies.  This was outside the scope of this study, 
but would be interesting to look at in future studies, in regards to age of onset, tau 
accumulation, neurodegeneration, and FKBP51 levels. This could also be done in a 
subpopulation of people with risk SNPs in FKBP5 which also have AD, if there is no 
SNP that is identified to increase risk for AD in the population as a whole. In addition, 
the mechanism of demethylation of the FKBP5 DNA, or the conclusion that this was the 
only mechanism leading to increased FKBP51 with aging, was not identified in this 
study.  
The roles of glucocorticoid receptors (GR) and tau212 and the role of GR and 
FKBP51 13 have now been clearly studied. A combined study of the role of FKBP51 
regulation of GR combined with tau pathology has not been performed, to date.  
Another pathway which has been studied separately is the role of FKPB51 in regulating 
AKT and the role of AKT in regulating tau. Given the central role of Hsp90 to both 
FKBP51 and AKT213, there is a clear link between these pathways which are implicated 
in both neurodegenerative diseases and cancers. More studies are needed to 
determine the role of FKBP51 and AKT together in tau biology. 
Overall our findings suggest there is an age-associated imbalance in the 
chaperone network, which could lead to toxic accumulation of tau. This work validates 
FKBP51 as a potential therapeutic target for the treatment of AD and other tauopathies. 
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Furthermore, the efforts of this study generated the first FKBP51 overexpressing mouse 
model to serve as a platform for the testing of new drugs as they are discovered.  
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APPENDIX B:  
IMMUNOHISTOCHEMISTRY HANDBOOK 
 
B.1 Order of events to prepare and process tissue 
1. Perfusion and preparation of brain tissue 
a. Mouse Perfusion with 0.9% Saline 
b. Tissue harvested for staining will be fixed in 4% paraformaldehyde for <24 
hours. 
c. Long-term storage of tissue in DPBS + 0.65% azide solution 
2. Cryopreservation and sectioning 
a. Before sectioning tissue for staining tissue is cryopreserved in sucrose 
gradients over 3 days. 
i. 10% sucrose for 24 hours 
ii. 20% sucrose for 24 hours 
iii. 30 % sucrose for 24 hours 
b. Sectioning (once the brain sinks in the 30% sucrose solution) is done by a 
sliding microtome with a freezing stage. 
3. Free-floating staining of proteins of interest, either brightfield or fluorescent. 
4. Stained tissue is mounted in mounting solution on charged glass slides and left 
to dry overnight 
5. The next day, tissue is dehydrated in serial ethanol solutions followed by clearing 
with histoclear before coverslipping using DPX and allowed to dry overnight 
6. Imaging is usually done using a Mirax slide scanner microscope after the slides 
have dried for at least 2 days. 
7. Images made by the slide scanner are segmented using NearCYTE for  desired 
regions of interest 
8. Segmented slides are batched analyzed for positive staining 
9. Analysis produced by IAE is sorted and analyzed by mouse and genotype and 
put into graphs 
10. Representative images are made to represent the results of the analysis 
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B 2 Perfusion and brain tissue preparation 
 
B2.1 Perfusion and fixing 
 
Mice are perfused transcardially using 20-50 mL of 0.9% saline until brain tissue is 
clear. The brain is removed and stored for the appropriate technique.  Most commonly 
the brain is divided down the midline, the right half of the brain is snap frozen cryotubes 
in dry ice or liquid nitrogen. The left hemisphere is put directly into 4% 
Paraformaldehyde (PFA) solution, where it will stay for up to 24 hours.  PFA creates 
crosslinks between aldehyde bonds, so the proteins stay in place as they were in the 
brain. The ideal fixing time for this tissue is between 6 and 24 hours, never fix for more 
than 24 hours. Before the 24 hour mark, PFA should be decanted off and replaced with 
DPBS + 0.65% azide solution for long-term storage of the tissue. 
***Handling mice, which includes this process, requires IACUC certification and 
training on handling and euthanatizing mice.   
 
Figure B1. Subdividing the brain for IHC and biochemistry 
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B 2.2 How to properly label tubes: 
Fixed tissue will go in these vials:  
 
Figure B2. Labelling tubes for fixed tissue 
These should be labelled on the lid and side with the study name/mouse number and 
the date in dark, thick sharpie as shown. Always write VERY clearly! 
Snap-frozen tissue will be placed in cryotubes: 
 
Figure B3. Labelling tubes for snap-frozen tissue 
These tubes should be color coded as they are labeled,  including: study name/mouse 
number on the top in dark thin sharpie and  name/mouse number, date, and the region 
(as described below) on the side 
Table B1: Cryotube Labelling Code 
Tube cap color Region Write on side 
Red Hippocampus HPC 
Orange Striatum STR 
Green Anterior 
Cortex 
ACX 
Yellow Posterior 
Cortex 
PCX 
Blue Cerebellum CER 
Purple Rest of brain ROB 
B 3 Cryopreservation and sectioning 
 
 
115 
 
B 3.1 Cryopreservation 
Before staining, the brain tissue must be sectioned. In order to prepare the tissue 
for sectioning, tissue must first be cryopreserved in sucrose gradients over 3 days.  
DPBS + sodium azide is decanted from the brain tissue and replaced with 10% 
sucrose and allowed to sit overnight. This process is repeated for two more days with 
20% and 30% sucrose solutions. Once the brain is at the bottom of the 30% sucrose 
solution, the brain is ready to be sectioned. This sucrose gradient pulls water out of the 
vessels in the brain and allows the brain to freeze without bursting these. This process 
is important; it prevents ice crystals from forming in the tissue. If the tissue is not 
properly preserved, it will cut poorly, be fragile, and break apart. As sucrose gradients 
are changes, this should be noted on the top of the brain tubes using tick marks 
representing each 10% of sucrose added to the tube. This allows for less confusion, 
especially when working on the same study with multiple people. 
 
Figure B4. Tick marks to show progression of fixed tissue through sucrose 
 
Sectioning is done on a sliding microtome with a freezing stage. Please see the 
following protocol for the full procedure, but I will walk you through the process now.  
First make sure you have plenty of chilled DPBS + 0.65% azide ready and at the 
correct pH. The brain is placed in freezing medium on a freezing stage, connected to a 
chilled water bath. This brain pictured below has been placed to section horizontally 
(i.e. the top of the brain as it sits in the mouse is still the top on the freezing stage). If 
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the brain is a hemisphere and not whole, there should be a clean cut down the center 
of the brain, this should always be perpendicular to the freezing stage, as shown in the 
picture below.  They will be white all the way through when completely frozen.  
  
Figure B5. Examples of horizontal tissue on freezing stage. (A) Half brains placed 
in glue waiting to freeze. (B) Frozen half brains and (C) whole brains which have been 
sectioned horizontally. 
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B 3.2 Sectioning 
B 3.2.1 Setting up 
The brain is sectioned at 25 µm into 24-well plates 2/3 filled with DPBS + 0.65% 
azide in each well. Trays should be labelled on the top with the name of the cohort 
name/mouse number, your initials, tray number/total trays, date, and double thick 
sectioned marked when appropriate.  The trays should also be labelled on the side with 
the cohort name/mouse number. When filling with DPBS + 0.65% azide, use a 25 mL 
serological pipet and pipette filler and make sure the solution is chilled and at pH 7.4.  
The pH of this solution is very important. 24-well plates need to be non-treated, or else 
the tissue will adhere to the bottom and be ruined. Always keep plates flat once filled.  
Tilting will cause tissue to be displaced from well 
Half brains need to be placed on the stage very carefully, as to not let them fall over 
in the glue.  Hold them vertical if necessary until the glue is frozen. 
Whole brains need to sit flat on the stage and will need to have a fiduciary mark 
(nick) put in the left side of the brain, as shown below.  
Figure B6. Fiduciary mark placement  
Figure B7. Important parts of the sliding microtome. 
 
 
118 
 
B 3.2.2 How to turn on the water bath  
Figure B8. How to turn on the water bath.  
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B 3.2.3 Sectioning horizontal sections 
 
1. At least 30 min before you are going to start, make sure the chiller is turned on 
and set to 5°C before you start (see B3.2.2) 
2. Set up: 
3. Make sure microtome is set to 25 um slices.  Adjust stage so the blade is above 
the stage with enough clearance so you can put the brain on and start at the top. 
4. Attach blade at about a 3° angle and as firmly as is possible. 
5. Place a cut square of paper towel on the stage, wet with water (not ethanol!) 
6. Always use flat sided forceps to handle brain 
7. Put brain on lid of vial in the appropriate position, so it is easy to put on the 
freezing stage 
8. If needed, trim brain stem so brain will be sitting evenly.   
9. Place a small amount of Tissue-Tek glue on the paper towel. 
10. Carefully place brain on glue.  It should be a flush horizontal and as straight 
vertical as possible.  Turn on freezing unit.  The button is in the back right of the 
machine.  Double check to make sure it is set to cool to -18C.  If needed, hold 
the brain with forceps until the bottom is frozen to ensure brain is sitting correctly. 
a. If working on more than one brain at a time put the brains in numerical 
order to avoid confusion. 
b. Do not section more than one brain at a time, until you are ready to do so. 
11. Cover brains with a weigh boat or bottle cap until frozen (this usually takes about 
15-20 min). 
a. Brain tissue will turn very white once completely frozen. 
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12. Any frost buildup can be brushed away with a makeup brush (used just for that 
purpose). 
13. Now adjust stage so blade is just above tissue and then roll forward and back 
until you slice the first piece of tissue.  It will be tiny. 
a. When moving over the tissue, move blade at a slow and steady rate.  It 
should be very even as you pass through the tissue to get nice, even 
slices. 
b. The blade should be very dry as it goes through the tissue, so dry the 
blade with a Kimwipe after each pass through the brain. 
14. Cut 25 sections and discard these (we collect the 26th onwards).  You will always 
hear a click when the stage moves up 25 um 
15. On the 26th section, wet paintbrush and in one motion roll/swipe the tissue off the 
blade. This should be done smoothly in one motion to avoid tearing any sections.  
Place tissue in the bottom of the appropriate well. Floating brain sections can 
dehydrate (and therefore become useless). Wipe blade, roll blade back (should 
always hear a click) and then proceed with the next section.  
a. Always have a dry blade and a wet paintbrush when sectioning, this will 
reduce damage to the tissue 
16. Continue sectioning until the whole brain is complete (once the brain is in 2 
pieces).   
17. Remove blade and put into oil or rust resistant paper, thaw the stage, wipe 
everything down, turn off water chiller and freezing unit.  Cover the microtome.  
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Put parafilm (2 ½ squares long, 2 squares wide) over the wells of the plate, then 
secure the lid of the plate.  Store at 4C until needed.   
18. Never tilt trays, always keep them flat! 
a. If you are sectioning more than one brain at a time, place the tissue in 
numerical order as you would read it, so you won’t forget which brain is 
where. 
b. Always clean up the area around the microtome, the sucrose can bring 
ants if not properly cleaned.  Rinse bench with water followed by 70% 
EtOH. 
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B 3.4. How to place sections into trays 
Table B2. Tray placement for tissue sectioned sequential no stereology: for 
injection studies. 
Place 24 well plates horizontally 
             
Depth 
(μm) 
1 3 5 7 9 11 13 15 17 19 21 23 25μm 1225 
2 4 6 8 10 12 14 16 18 20 22 24     
25 27 29 31 33 35 37 39 41 43 45 47 25μm 1825 
26 28 30 32 34 36 38 40 42 44 46 48     
49 51 53 55 57 59 61 63 65 67 69 71 25μm 2425 
50 52 54 56 58 60 62 64 66 68 70 72     
73 75 77 79 81 83 85 87 89 91 93 95 25μm 3025 
74 76 78 80 82 84 86 88 90 92 94 96     
                
97 99 101 103 105 107 109 111 113 115 117 119 25μm 3625 
98 100 102 104 106 108 110 112 114 116 118 120     
121 123 125 127 129 131 133 135 137 139 141 143 25μm 4225 
122 124 126 128 130 132 134 136 138 140 142 144     
145 147 149 151 172 174 176 178 181 183 185 187 25μm 4825 
146 148 150 170 173 175 177 179 182 184 186 188     
189 191 193 195 197 199 201 203 205 207 209 211 25μm 5425 
190 192 194 196 198 200 202 204 206 208 210 212     
Section 1 here is really the 26th section 
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Table B3. Tray placement for tissue sectioned sequentially with stereology every 
8th section: for injection studies. 
Place 24 well plates horizontally (Section 1 here is really the 26th 
section) 
  
Depth 
(μm) 
1 3 5 7 9 11 13 15 17 19 21 23 25μm 1300 
2 4 6   10 12 14   18 20 22       
25 27 29 31 33 35 37 39 41 43 45 47 25μm 1975 
26 28 30   34 36 38   42 44 46       
49 51 53 55 57 58 61 63 65 67 69 71 25μm 2650 
50 52 54   58 60 62   66 68 70       
73 75 77 79 81 83 85 87 89 91 93 95 25μm 3325 
74 76 78   82 84 86   90 92 94       
                
97 99 101 103 105 107 109 111 113 115 117 119 25μm 4000 
98 100 102   106 108 110   114 116 118       
121 123 125 127 129 131 133 135 137 139 141 143 25μm 4675 
122 124 126   130 132 134   138 140 142       
145 147 149 151 153 155 157 159 161 163 165 167 25μm 5350 
146 148 150   154 156 158   162 164 166       
8 16 40 56 72 88 104 120 136 152 168   50μm   
24 32 48 64 80 96 112 128 144 160         
Table B4. Tray placement for tissue sectioned non-sequential with stereology 
every 8th section: for whole brain treatments or no treatment. 
Place 24 well plates vertically(Section 1 here is really the 26th section) 
1 97 2 98 3 99 4 100  5 101 6 102 7 103 8 104 
49 145 50 146 51 147 52 148  53 149 54 150 55 151 56 152 
9 105 10 106 11 107 12 108  13 109 14 110 15 111 16 112 
57 153 58 154 59 155 60 156  61 157 62 158 63 159 64 160 
17 113 18 114 19 115 20 116  21 117 22 118 23 119 24 120 
65 161 66 162 67 163 68 164  69 165 70 166 71 167 72 168 
25 121 26 122 27 123 28 124  29 125 30 126 31 127 32 128 
73 169 74 170 75 171 76 172  77 173 78 174 79 175 80 176 
33 129 34 130 35 131 36 132  37 133 38 134 39 135 40 136 
81 177 82 178 83 179 84 180  85 181 86 182 87 183 88 184 
41 137 42 138 43 139 44 140  45 141 46 142 47 143 48 144 
89 185 90 186 91 187 92 188  93 189 94 190 95 191 96 192 
25μm 25μm 25μm 25μm  25μm 25μm 25μm 50μm 
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B4 Staining   
B4.1 Background 
We use free-floating sections to stain for proteins of interest in brain tissue sections.  
Figure B9. Schematic of brightfield staining (Indirect). 
Figure B10. Schematic of fluorescent staining (Direct). 
Simply, tissue is blocked for endogenous peroxidases, cells are permeabilized 
with triton,  antibody for the protein of interest (known as primary antibody) is added, 
antibodies towards  the animal the primary antibody was grown in is added (known as 
the secondary antibody).  This is precipitated out and colorized by a DAB/Nickel 
reaction. 
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Antibodies are produced by injecting animals with the protein/peptide which 
needs to be recognized. Primary antibodies are produced by injecting a small animal 
(most commonly a mouse or rabbit) with the specific protein you are interested in. 
Secondary antibodies are made by injecting protein specific to the species of the 
primary antibody.  You will be using serum to block during multiple steps, the choice of 
serum is determined by the animal the secondary antibody is grown in. 
For example, a common antibody we use to recognize tau is rabbit anti-H150 
tau.  This is the primary antibody, which was grown in a rabbit towards tau amino acids 
1-150. The secondary antibody would then be directed towards rabbit protein and also 
should be tagged with a biotin, such as goat anti-rabbit BIOT. The biotin allows us to 
precipitate out the complex and colorize it for staining. The serum to block with in this 
example would be goat serum, since the secondary antibody was made in a goat. 
To set up a stain, you will need to calculate the number of wells needed for the 
stain.  This will be based on the number of mice and number of sections used per 
mouse, keeping in mind that whole brain tissues should be placed in the wells at 2 or 
less sections per well, and half brains placed in wells at 3 sections per well or less if 
possible. Also, use the small trays whenever possible to reduce reagent use. The small 
trays are 8 x 5 wells (40 wells total) and use 40 mLs total of solution for each step. The 
large trays are 12 x 8 (96 wells total) and use 100 mLs total solution for each step. 
The choice tissue is selected based on the treatment of the mice in the cohort.  
Most commonly, tissue is selected to represent the whole brain or to show the region 
surrounding an injection site. This selected tissue should be added a piece at a time 
and marked on the tray map (shown in Figure B11), so the tissue will not be confused. 
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This should also include the date of the stain, your initials, and the concentrations of 
primary and secondary antibody used, as well as any other important notes for that 
stain.  
    Figure B11. Example tray map of tissue sections. 
  
A characterization is done on each new antibody used for staining. This is done by 
performing the stain as described in the protocol, but with using different primary 
antibody concentrations.  This is done by making serial dilutions of primary antibody in 
PBS and serum as shown below. Use a non-treated 24 well plate with >300 µL per well, 
with tissue from one mouse at one concentration of antibody per well. Load tissue 
selected for no primary first, followed by loading the tissue for the other concentrations, 
up to the highest concentration.  The highest concentration of antibody will depend on 
the manufacture’s suggestions but usually is around 1:100-1:300. 
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Table B5. Antibody characterization setup 
Antibody Concentration PBS Serum 1° Antibody 
1:300 120 µL 2.875 mL 10 µL of Antibody 
1:1K 84 µL 1.915 mL 1mL of 1:300 
1:3K 84 µL 1.915 mL 1mL of 1:1K 
1:10K 84 µL 1.915 mL 1mL of 1:3K 
1:30K 84 µL 1.915 mL 1mL of 1:10K 
No 1° 84 µL 1.915 mL No Primary 
Additional notes: 
• New antibodies which have not been characterized in our lab, must first be 
characterized before using for a full stain.  
• Always remove sections in netted trays from liquid when moving to prevent spilling 
of tissue into the wrong wells 
• Tissue can be paused at any PBS step, but it is preferable if run as listed in the 
protocol. Keep trays shut/covered when pausing and put in 4C walk-in fridge if it will 
be more than 24 hours. 
• Always start with PBS (or TBS) and add each ingredient to it, from least to most 
expensive (typically the largest volume to the smallest volume) 
• Reagents: 
L-Lysine Monohydrochloride Fisher Cat# AC125222500 
Triton-X 100 Fisher Cat# BP151-500 
Goat Serum (Filtered) Fisher Cat# 50-412-961 
Donkey Serum (Filtered) Lampire Cat# 7332100 
3,3’ Diaminobenzidine tetrahydrochloride (DAB) Sigma Cat# D5637 
Nickel Ammonium Sulfate   Fisher Cat# N48-500 
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Figure B12. Staining tray map blank sheet for small tray 
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B4.2 Brightfield IHC protocol (Small) 
1. Get a purple tray labeled wash 1 and fill with 40 mL PBS 
2. Put in small netting and put in selected sections. 
3. Block endogenous peroxidases: 
PBS 32 mL 
Methanol (shelf) 4   mL 
30% H202 (4°C) 4   mL  
Incubate 15 minutes at room temperature on shaker.  
Remove ~6mL serum from -20°C freezer and thaw in hot water for step 
*Label with today’s date, store at 4°C once thawed, use within 24 hours. 
4. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking. 
5. Permeabilize tissue:  · 
                     PBS                                30.4 mL     
Lysine (shelf)         0.7 g 
1% triton-x-100 in water (shelf)            8 mL 
 _________ Serum                 1.6 mL 
Incubate 30 minutes at RT with shaking 
6. Remove control sections and place into PBS with 4% serum. 
7. Primary Antibody Incubation: 
  PBS         38.4 mL 
  Serum                  1.6 mL 
           Antibody: __________ (1:______) _____ µL 
8. Cover with foil, shake for 1 hour, let incubate overnight. 
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Day 2 
1. Shake 60 minutes 
2. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking. 
3. Secondary Antibody 
  PBS          38.4 mL 
  Serum          1.6 mL 
           Antibody: __________ (1:______) _____ µL 
Incubate for 2 hours at RT with shaking, but set a timer for 1 hour 
and 45 minutes.Once timer goes off, make ABC solution (4°C): 4 
drops each A and B in 40 mL PBS. Set this on a shaker to 
incubate for 30 minutes, you will use this in step 5. 
4. Wash 40 mL PBS 3x, 5 minutes each with shaking. 
5. ABC (once conjugated for 30 minutes) 
Incubate for 1 hour at RT with shaking 
6. Wash 2x: 40 mL PBS 2x, 5 minutes each with shaking 
7. Wash 1x: 40 mL TBS (fresh) for 5 min with shaking (if using Ni++) 
8. Prepare DAB/Nickel for next step: Measure DAB and Nickel in 2 separate 50 
mL tubes; get into solution <15 minutes before DAB/Nickel step.  Only mix 
together less than 1 minute before step 9. 
9. DAB/Nickel 
a. TBS (made fresh)             40 mL 
b. DAB (in freezer door)      20 mg 
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c. Nickel Ammonium Sulfate  (shelf)    200 mg 
d. Incubate 5 minutes with shaking 
10.  Color Development **DO NOT POUR DOWN THE SINK*** 
a. Remove tissue from solution 
b. Add 40 µL H2O2 (4°C) to DAB/Nickel solution 
c. Shake for 30 seconds 
d. Add tissue back into tray 
e. Incubate for 5 minutes with shaking 
f. Pour into liquid waste after step 
11.  Wash 40  mL TBS, 5 minutes  
12.  Wash 2x: 40 mL PBS 2x, 5 minutes each with shaking. 
13.  Mount tissue and allow to dry overnight, before dehydrating 
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B4.3 Fluorescent protocol (Small) 
1. Get a purple tray labeled wash 1 and fill with 40 mL PBS 
2. Put in small netting and put in selected sections. 
Remove ~6mL serum from -20°C freezer and thaw in hot water for step 
5. Label with today’s date, store at 4°C once thawed. 
3. Permeabilize tissue:  · 
                     PBS                                30.4 mL     
Lysine (shelf)         0.7  g 
1% triton-x-100 in water (shelf)            8 mL 
 _________ Serum                 1.6 mL 
Incubate 30 minutes at RT with shaking 
4. Remove control sections and place into PBS with 4% serum. 
5. Primary Antibody Incubation: 
  PBS         38.4 mL 
  Serum                 1.6 mL 
           Antibody(s): __________ (1:______) _____ µL 
6. Cover with foil, shake for 1 hour, let incubate overnight. 
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Day 2 
  7.  Shake 60 minutes 
8. Wash 3x: 40 mL PBS 3x, 5 minutes each with shaking. 
9. Secondary Antibody 
  PBS                 38.4 mL 
  Serum        1.6 mL 
           Antibody(s): __________ (1:______) _____ µL 
Incubate for 2 hours at RT with shaking. 
10.   Wash 40 mL PBS 3x, 5 minutes each with shaking. 
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Figure B13. Staining tray map blank sheet for large tray   
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B4.4 Brightfield IHC protocol (Large) 
1. Get a large clear tray labeled PBS and fill with 100 mL PBS 
2. Put in large netting and put in selected sections. 
3. Block endogenous peroxidases: 
PBS  80 mL 
Methanol (shelf) 10 mL 
30% H202 (4°C) 10 mL  
Incubate 15 minutes at room temperature on shaker.  
Remove ~12 mL serum from -20°C freezer and thaw in hot water for 
step 4. Label with today’s date, store at 4°C once thawed. 
3. Wash 100 mL PBS 3x, 5 minutes each with shaking. 
4 . Permeabilize tissue: · 
                      PBS                                    76 mL     
Lysine (shelf)           1.83 g 
1% triton-x-100 in water (shelf)             20 mL 
 _________ Serum                     4 mL 
Incubate 30 minutes at RT with shaking 
5 . Remove control sections and place into PBS with 4% serum. 
6. Primary Antibody Incubation: 
  PBS             95 mL 
  Serum                      4 mL 
                    Antibody: __________ (1:______) _____ µL 
7. Cover with foil, shake for 1 hour, let incubate overnight. 
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Day 2 
1. Shake 60 minutes 
2. Wash 100 mL PBS 3x, 5 minutes each with shaking. 
3. Secondary Antibody 
  PBS            95 mL 
  Serum             4 mL 
               Antibody: __________ (1:______) _____ µL 
Incubate for 2 hours at RT with shaking, but set a timer for 1 hour and 
45 minutes. Once timer goes off, make ABC solution (4°C): 8 drops 
each A and B in 100 mL PBS. Set this on a shaker to incubate for 30 
minutes, you will use this in step 5. 
4. Wash 100 mL PBS 3x, 5 minutes each with shaking. 
5. ABC (once conjugated for 30 minutes) 
Incubate for 1 hour at RT with shaking 
6. Wash 100 mL PBS 2x, 5 minutes each with shaking 
7. Wash 100 mL TBS (fresh) 1x for 5 min with shaking (if using Ni++) 
8. Prepare DAB/Nickel for next step: Measure DAB and Nickel in 2 separate 50 
mL tubes; get into solution <15 minutes before DAB/Nickel step.  Only mix 
together <1 minute before step 9. 
9. DAB/Nickel 
a. TBS (made fresh)           100 mL 
b. DAB (in freezer door)      50 mg 
c. Nickel Ammonium Sulfate  (shelf)    500 mg 
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d. Incubate 5 minutes with shaking 
10.  Color Development **DO NOT POUR DOWN THE SINK*** 
a. Remove tissue from solution 
b. Add 100µL H2O2 (4°C) to DAB/Nickel solution 
c. Shake for 30 seconds 
d. Add tissue back into tray 
e. Incubate for 5 minutes with shaking 
f. Pour into liquid waste after step 
11.  Wash 100 mL TBS, 5 minutes  
**Bleach tray after step 
12.  Wash 100 mL PBS 2x, 5 minutes each with shaking. 
13.  Mount tissue and allow to dry overnight, then dehydrate 
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B4.5 Fluorescent protocol (Large) 
1. Get a large tray labeled wash 1 and fill with 100 mL PBS 
2. Put in small netting and put in selected sections. 
Remove ~12 mL serum from -20°C freezer and thaw in hot water for 
step *Label with today’s date, store at 4°C once thawed. 
3. Permeabilize tissue:   
PBS                                      76 mL     
Lysine (shelf)            1.83 g 
1% triton-x-100 in water (shelf)              20 mL 
 _________ Serum                      4 mL 
Incubate 30 minutes at RT with shaking 
4. Remove control sections and place into PBS with 4% serum. 
5. Primary Antibody Incubation: 
  PBS               95 mL 
  Serum                        4 mL 
                    Antibody(s): __________ (1:______) _____ µL 
6. Cover with foil, shake for 1 hour, let incubate overnight. 
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Day 2 
    7. Shake 60 minutes 
8. Wash 100 mL PBS 3x, 5 minutes each with shaking. 
9. Secondary Antibody KEEP AWAY FROM LIGHT FROM HERE ON 
  PBS               95 mL 
  Serum     4 mL 
               Antibody(s): __________ (1:______) _____ µL 
Incubate for 2 hours at RT with shaking. 
10.  Wash 100 mL PBS 3x, 5 minutes each with shaking. 
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B4.6 Characterized antibodies 
 
Table B6. Characterized antibodies for immunohistochemistry. 
 
1° Antibody Concentration 2
° 
Antibody Concentration Serum 
Company; 
Catalog # 
Storag
e 
Neu N Biotin 1:3K - - Goat Milliopore; 
MAB377BMI  
4°C 
Hsp27 (C-20) 1:5K α-Goat 1:200 Donkey Santa Cruz; 
sc-1048 
4°C 
Tia1 (C-20) 1:2500 α-Goat 1:500 Donkey Santa Cruz; 
Sc-1751  
-20°C 
AT8 
(pS202,205) 
1:5K α-Mouse 1:3K Goat Thermo -20°C 
12E8 
(pS262,356) 
1:10K α-Mouse 1:3K Goat Peter Davies -20°C 
CP13 (pS199, 
202, 205) 
1:3K α-Mouse 1:3K Goat Peter Davies -20°C 
HSP40 1:100 α-Mouse 1:3K Goat Stressmarq; 
SPC-100D 
-20°C 
Hsp90-10 (90β) 1:300 α-Mouse 1:3K Goat  David Toft -20°C 
MC1 
(conformation) 
1:10K α-Mouse 1:3K Goat Peter Davies -20°C 
NY18 1:10K α-Mouse 1:3K Goat Lester 
Binder  
-20°C 
P23 (JJ3) 1:600 α-Mouse 1:3K Goat  Fisher Sci; 
MA3414 
 -20°C 
PHF1 
(pS396;404) 
1:5K α-Mouse 1:3K Goat Peter Davies -20°C 
PHF6 (pT231) 1:100K α-Mouse 1:20K Goat  Abcam; 
ab24594 
-20°C 
PHF6 (pT231) 1:3K α-Mouse 1:20K Goat  Abcam; 
ab24594  
-20°C 
Tau C3 1:10K α-Mouse 1:3K Goat  Lester 
Binder  
-20°C 
Tg3 1:300 α-Mouse 1:3K Goat Peter 
Davies   
-20°C 
Aβ 1:10K α-Rabbit 1:3K Goat Paul 
Gottschall  
-20°C 
Calpain 1 1:1K α-Rabbit 1:10K Goat Abcam; 
632498 
-20°C 
CDC37 1:100 α-Rabbit 1:3K Goat Cell Signal; 
570172 
-20°C 
FIZZ-1 1:5K α-Rabbit 1:3K Goat     
GFP 1:1K α-Rabbit 1:10K Goat  Invitrogen -20°C 
GRP94 1:10K α-Rabbit 1:10K Goat Cell Signal; 
2104S 
-20°C 
H150 1:5K α-Rabbit 1:10K Goat Santa Cruz; 
sc 5587 
4°C 
Tau pS199-202  
on rTg4510 
mice 
1:65K α-Rabbit 1:3K Goat AnaSpec; 
54963-025  
4°C 
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Tau pS199-202 
on wild-type 
mice 
1:20K α-Rabbit 1:3K Goat AnaSpec; 
54963-025  
4°C 
Tau pT212 on 
wild-type mice 
1:1K α-Rabbit 1:10K Goat AnaSpec; 
54966-025  
4°C 
Tau pS214 on 
rTg4510 mice 
1:1K α-Rabbit 1:3K Goat AnaSpec; 
54967-025 
4°C 
Tau pS214 on 
wild-type mice 
1:300 α-Rabbit 1:3K Goat AnaSpec; 
54967-025 
4°C 
Tau pT231 on 
rTg4510 mice 
1:300 α-Rabbit 1:10K Goat AnaSpec; 
55313-025 
4°C 
Tau pS262 on 
rTg4510 mice 
1:1K α-Rabbit 1:10K Goat AnaSpec; 
54973 
4°C 
Tau pS396 on 
rTg4510 mice 
1:30K α-Rabbit 1:10K Goat AnaSpec; 
9632S 
4°C 
Tau pS396 on 
wild-type mice 
1:5K α-Rabbit 1:10K Goat AnaSpec; 
9632S 
4°C 
Synaptophisin 1:3K α-Rabbit 1:10K Goat   4°C 
YM-1 1:5K α-Rabbit 1:10K Goat Stem Cell 
Tech; 1404 
 -20°C 
CD 33 (M-90) 1:300 α-Rabbit 1:3K Goat Santa Cruz; 
SC-28810 
-20°C 
FKBP51  1:2K α-Rabbit 1:10K Goat Cell Signal; 
8245S 
-20°C 
CD3 1:10K α-Rat 1:1K Goat AbD serotec; 
MCA500GA 
4°C 
CD4 1:30K α-Rat 1:1K Goat AbD serotec; 
MCA4635GA 
-20°C 
CD8 1:30K α-Rat 1:1K Goat AbD serotec; 
MCA609G 
4°C 
CD45 1:10K α-Rat 1:1K Goat AbD Serotec; 
MCA1031G 
4°C 
Fc-y 
CD16/CD32 
1:1K α-Rat 1:1K Goat BD Bio; 
553140 
 4°C 
HSC70 1:30K α-Rat 1:1K Goat Stressgen; 
SPA-815F 
-20°C 
MHCII 1:5K α-Rat 1:1K Goat BD 
Pharmigen  
  
BrdU 1:200 α-Rat 1:1K Goat AbD serotec; 
MCA2060T  
4°C 
       
Biotinylated secondary antibodies are all from Southern Biotehnologies. 
Swine α-Goat- IgG BIOT Cat# 3600-08, Goat α-Mouse IgG BIOT Cat# 1030-08, Goat α-
Rabbit IgG BIOT Cat#4030-08, Goat α-Rat IgG BIOT Cat#3010-08 
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Table B7. Characterized antibodies for immunofluorescence 
1° 
Antibody Concentration 
2°  
Alexafluor 
Antibody 
Concentration Serum Company/ Catalog # Storage 
Tau 
pS199-202 
1:1K α-Rabbit 1:3K Goat AnaSpec; 
54963-025  
4°C 
Tau pS396 1:1K α-Rabbit 1:3K Goat AnaSpec; 
9632S 
4°C 
FKBP51 1:300 α-Rabbit 1:3K Goat Cell Signal; 
8245S 
-20°C 
Hsp27  
(c-20) 
1:1K α-Goat 1:1K Donke
y 
Santa Cruz; sc-
1048 
4°C 
Tau  
(V-20) 
1:50 α-Goat 1:1000 Donke
y 
Santa Cruz; sc-
1996 
4°C 
Tau 1:1K α-Chicken 1:3K Goat Neuromics; 
CH23018  
-20°C 
Hsc70 1:100 α-Rat 1:3K Goat Stressgen; 
SPA-815F 
-20°C 
Hsc70 
Biotin 
  Streptavidin 1:3K Goat Abcam; 
ab69558 
-20°C 
NeuN 
Biotin 
1:100 Streptavidin 1:1K 1:1K Milliopore; 
MAB377BMI 
4°C 
Hsp90-10 
(90β) 
1:300 α-Mouse 1:3K Goat  David Toft -20°C 
NeuN 1:100 α-Mouse 1:3K Goat Milliopore; 
MAB377BMI 
4°C 
GR 1:100 α-Rabbit 1:1K Goat Cell Signal; 
7437S 
-20°C 
 Alexaflour secondary antibodies are all from Invitrogen. 
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B4.7. Other non-standard stains: 
B4.7.1 Gallyas silverstain  
B4.7.1.1 Reagents 
Periodic Acid Fisher Scientific Cat# AC198401000 
Potassium iodide Sigma Cat# 746428 
Sodium hydroxide Fisher Scientific Cat# S318-3  
Acetic Acid (glacial) Fisher Scientific Cat# AC1489300010 
Sodium Carbonate (anhydrous) Sigma Cat# 223484 
Ammonium nitrate          Sigma Cat# 221244 
Silver nitrate               Sigma Cat# 209139 
37% Formaldehyde        Sigma Cat# 252549 
Tungstosilicic acid         Sigma Cat# 383341 
Sodium thiosulfate Sigma Cat#72049 
Gold (III) chloride trihydrate Sigma Cat# G4022 
B4.7.1.2 Making Solutions 
1. 5% Periodic Acid 
1. Periodic acid   25g  
2. Distilled water      500mL  
2. Alkaline Silver Iodide Solution 
1. sodium hydroxide  40g  
2. potassium iodide 100g  
3. Distilled water      500mL  
4. 1% silver nitrate  35mL 
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Dissolve the sodium hydroxide in water then add the potassium iodide and wait till 
dissolved. Slowly add the silver nitrate and stir vigorously. Then add distilled water to 
give a final volume of 1000mL  
3. 0.5% Acetic Acid (need for 2 steps) 
1. Glacial Acetic Acid 2.5 mL 
2. Distilled water             497.5 mL 
4. Stock Solution I 
1. Sodium Carbonate 50g 
(Anhydrous)  
2. Distilled water              1000 mL  
5. Stock Solution II 
1. Distilled water          1000 mL 
2. Ammonium nitrate       2 g 
3. Silver nitrate               2 g 
4. Tungstosilicic acid      10 g 
6. Stock Solution III 
1. Distilled water               1000 mL 
2. Ammonium nitrate    2 g 
3. Silver nitrate                 2 g 
4. Tungstosilicic acid        10 g 
5. 37% Formaldehyde       7.3 mL  
7. 0.1% Gold Chloride (keep from light) 
1. gold chloride  1 g 
2. Distilled water               1000 mL 
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8. 1% Sodium Thiosulfate 
1. sodium  thiosulfate 5g 
2.  Distilled water              500 mL 
9. Neutral Fast Red 
1. Neutral fast red     2mL 
(Solution) 
2. Distilled water 200 mL 
 
B4.7.1.3 Procedure 
1. Mount sections on slides and air dry overnight 
2. Hydrate sections in water 30 dips 
3. Place in 5% periodic acid for 5 min 
4. Wash in distilled water for 2 x 5 min 
5. Place in alkaline silver iodide solution for 1 min 
6. Wash in 0.5% acetic acid for 10 min 
Place in developer solution (Prepare immediately before use) 
Add 3x Stock II to 10x Stock I. Stir, then add 7x Stock III 
(i.e. 240 mL stock II, 800 mL stock I, 560 mL stock III) 
 ***Put 3 rubber bands around slide racks, and place in leak proof container. Rock 
continuously and tilt every way the entire time during this step. 
Developer solution for 5-15 minutes, watch by eye and allow stain to go slightly too 
dark, as it will lighten up in the following steps 
8. Wash in 0.5% acetic acid for 3 min 
9. Wash in distilled water for 5 minutes 
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10. Place in 0.1% gold chloride for 5 min (keep from light) 
11. Rinse in distilled water for 1 min 
12. Place in 1% sodium thiosulphate solution for 5 min 
13. Wash in tap water for 1 min 
14. Incubate in filtered 1% neutral red solution (can skip this if no counterstain is 
desired) for 1 min 
15. Rinse in tap water 3 x 1 min 
16. Dip 8 times in 95% EtOH 
17. Dip 8 times 2 x 100% EtOH 
18. Clear in Xylene 3 x 5 min 
19. Coverslip using DPX 
 
Tangles will be black and nuclei will be red.  
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B4.7.2 Cresyl violet (Nissl) 
1. Mount sections on slides and air dry overnight 
2. Hydrate sections in water 10 dips 
3. Stain in 0.05% cresyl violet for 5 minutes (or less if lighter color is desired) 
4. Destain in acidic water for 30 dips or until desired color 
5. Rinse in water 10 dips 
6. Dehydrate through graded ethanol series 
75% EtOH 30 dips 
95% EtOH 30 dips 
100% EtOH 30 dips 
7. Clear in histoclear, 3 x 5 min each 
8. Coverslip with DPX 
9. Filter Cresyl violet solution after use 
10. Rinse out blue ethanols and remake 
  
   
Solutions: 
 Cresyl Violet: 0.05% in water, pH 3.3 with acetic acid 
Add 0.25g dye to 500mL water, stir 1 hour and adjust pH 
Keep from light 
Acidic Water: 6 drops acetic acid per 200mL water 
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B4.7.3 Hematoxylin (Nuclei) and eosin (cytoplasm) 
1. Mount tissue and allow to dry over night 
2. Rehydrate in ddH2O 
3. While sections are in water, filter hematoxaline and pour into dish. Skim surface 
of hematoxalin with a Kimwipe to remove oxidized particles. Blot excess water 
from slide holder before going into hematoxalin 
4. Incubate in hematoxalin for 3 minutes. 
5. Rinse in ddH2O for 30 sec 
6. Wash in tap water for 5 minutes (to allow stain to develop) 
7. Dip quickly 8-12x times in acid ethanol (to destain) 
a. 151.65 mL 95% EtOH 
b. 55.88 ddH2O 
c. 0.529 HCl (conc.) 
8. Rinse 2x in tap water for 1 minute 
9. Blue in 0.2% ammonia Water solution 
a. 400uL ammonium hydroxide conc. per 200mL ddH2O 
10. Rinse 1 time in ddH2O for 2 minutes (can leave overnight if needed at this 
stage) 
11. Blot excess water from slide holder on paper towel 
12. Incubate in Eosin solution for 10 seconds (older solutions may take up to 45 
seconds) 
a. 2.5g eosin 
b. 495 mL H2O 
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c. 0.5 mL glacial acetic acid 
13. Dehydrate in 95% EtOH 3x for 5 minutes 
14. Dehydrate in 100% EtOH 3x for 5 minutes 
15. Clear in Xylenes 3x for 5 minutes 
16.  Coverslip with DPX  
17. Lay slides flat on a tray and allow to dry overnight 
***Eosin can interfere with other stains, so dishware should be labeled for only this 
purpose  
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B4.7.4 Prussian Blue (Iron stain for microhemorrhage) 
***Make neutral red solution the night before 
***Steps 1-5, glassware needs to be clean and to not have any tap water, this 
contains iron which will affect the reaction 
***Prolonged washing in water and ethanol will reduce the neutral red staining 
1. Mount sections on slides and air dry overnight 
2. In separate containers make: 
a. 2 mL conc. HCl + 98 mL ddH2O 
b. 2g potassium ferrocyanide + 100 mL ddH2O 
3. Mix a and b. immediately before use 
4. Rehydrate sections in distilled water for 30 seconds 
5. Incubate in a. and b. mixture for 15 minutes 
6. Rinse two times in distilled water for 30 seconds 
7. Rinse once in tap water for 5 minutes 
8. Rinse slides in ddH2O for 30 seconds 
9. Incubate in filtered 1% neutral red solution for 1 minute 
a. 2g neutral red  
b. 200 mL ddH2O   
10. Rinse through three changes of tap water for 1 minute each 
11. Dip 8 times in 95% EtOH 
12. Dip 8 tims through 2 changes of 100% EtOH 
13. Clear in xylenex 3x for 5 minutes each 
14. Coverslip with DPX 
15. Lay on tray and allow to dry overnight 
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B4.7.5 NeuroTrace® 640 (Flourescent Nissl Stain) 
Modified from datasheet by Moleular probes CAT # N21483 
Stored in -20C 
1. Mount after antibody stain and let sit overnight. 
2. Rehydrate slide in PBS for 40 minutes. 
3. Wash in 0.1% Triton-X+PBS for 10 minutes 
4. Wash 2x in PBS for 5 minutes. 
5. Dilute Neurotrace 1:25 in PBS. 
6. Apply 200 uL to cover each section for 20 minutes. 
7. Wash in 0.1% Triton-X for 10 minutes. 
8. Wash 2x in PBS for 5 minutes. 
9. Coverslip 
10. Store at 4◦ 
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B4.7.6 Thioflavin S 
1. Mount sections on slides and air dry over night 
2. Hydrate sections in ddH2O for ~30 seconds 
3. Blot rack on paper towel 
4. Stain in Mayer’s hematoxylin for 2 minutes (to block nuclear fluorescence 
and establish a background)- this solution is reusable and should be 
filtered  
5. To convert red hematoxylin to blue, place slides in ammonia water (10 
drops NH4OH conc. in 200 mL ddH2O for ~30 sec) 
6. Rinse in ddH2O for  3 minutes 
7. Rinse two more times in ddH2O for 2 minutes each 
8. Turn off lights or work in dim lighting 
9. Stain sections for 10 minutes in a 1% Thioflavine-S solution (2g ThS in 
200 mL ddH2O). 
10. Wash in ddH2O two times for 30 seconds each 
11. Wash in 75% EtOH for 30 seconds 
12. Dehydrate in 100% EtOH for 1 minutes (any longer will destain) 
13. Clear in xylenes 3x for 5 minutes each 
14. Coverslip with DPX and allow to dry on tray overnight. 
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B4.7.7 Β-Galactosidase stain 
Day 1 
1. Prepare staining solution 
a. Dilute one part 100x X-Gal solution with 99 parts staining buffer 
i. (*24 well plate—total volume = 6 mL – prepare 7 mL 
ii. 6.93 mL staining buffer 
iii. 70 μL X-Gal Solution 
b. Add 0.02% NP40 and 0.01% DOC into staining solution 
i. 140 μL NP40 
ii. 70 μL DOC 
2. Add staining solution to tissue culture dish 
i. 0.25 mL per well 
3. Add sections to tissue culture dish 
4. Incubate sections overnight at 37ºC 
Day 2 
1. Remove dish from heat 
2. Prepare 1x PBS by diluting 1 part 10x PBS with 9 parts diH20 
a. (*24 well plate—total volume = 40 mL = 0.5mL/ well 
b. 36 mL diH20 
c. 4 mL 10x PBS 
3. Add 1x PBS to new tissue culture dish 
4. Add sections to 1x PBS, wash 5 min 
5. Repeat 3x 
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B4.7.8 Sudan Black (for fluorescent staining of tissue with high background) 
After staining and counterstaining are complete: 
1. Incubate tissue in 0.1% Sudan Black B solution in 70% EtOH for 20 
minutes 
a. 40 mg in 40 mL 
b. 100 mg in 100 mL 
2. Wash with PBS + 0.02% Tween-20 4x for 5 minutes each  
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B4.7.9 BrdU immunostaining protocol 
***Mice must first be given BrdU via IP or drinking water. 
1. 20 min 3% H2O2 – only if DAB (blocks endogenous peroxidase in blood) 
2. PB wash, 2x – 5-10 min 
3. 1 hour incubation @ 55°C: 50% Formamide, 50% 4x SSC 
4. Rapid wash sections in 2x SSC (opens DNA strands) 
5. 30 min incubation in 2N HCl @ 37°C 
a. 6.68 mL conc HCl in 40 mL PBS 
6. 0.1M Boric Acid wash (neutralize 2N HCl), 2 min  
a. 0.2472g in 40 mL PBS 
7. PBS wash, 3x – 5-10 min 
***If desired, can continue with normal staining process from this point on; start at 
permeablilization step*** 
8. 1 hour incubation in blocking solution 
90% PBS-Tx 0.25%, 10% Goat Serum 
9. Overnight incubation in primary anitbody in cold room. 
Rat anti-BrdU, 1:200 in blocking solution AbD Serotec #MCA2060T 
10. PBS wash, 3x – 5-10min 
11. 1 hour incubation in Secondary Antibody @ room temp. 
*Biotinlyated goat anti-rat IgG, 1:200 in blocking solution 
12. PBS wash, 3x – 5-10min 
13. 45 minute incubation in ABC (Avidin-Biotin Complex) 
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*Prepare ABC 30-45 minutes before usage.  Use different pipette tip for each 
component to avoid contamination of stock solutions. 
*1:300 A, 1:300 B in 0.1M PB  
14. PBS wash, 4x – 5-10min (minimize background) 
15. DAB (until sections begin to turn brown) inside hood 
*Solution Prep: 1 mL DAB in 60 mL PB (-80°C Freezer).  Add 100 µl H2O2 right 
before addition to sections 
*Filter DAB solution as adding to sections 
*Use bleach to clean/dispose of DAB 
16. Rapid wash w/ dH2O (4°C) 
17. PBS wash, 3x – 5-10min 
18. Keep sections in foil at 4°C until mounting  
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B4.7.10 Congo red 
1. Mount slides and dry overnight   
2. Clean 9 glass dishes and label: 
o diH2O 
o Alkaline Sodium Chloride Solution 
o Congo 
o 95% EtOH 
o 100% EtOH 
o 100% EtOH 
o Prepare 3 Xylene 
3. Hydrate in diH2Ofor 10 dips 
4. Incubate in Alkaline Sodium Chloride for 20 minutes 
(Just prior to use add 2 mL NaOH to 198 mL Sat. Alcoholic Sodium Chloride) 
5. Congo Red- 15 minutes 
a. Make within 15 minutes of use 
b. Add 2 mL 1M NaOH to 198 mL Congo 
c. Filter solution 
d. Clean glassware immediately 
6. 1X 95% EtOH for 3 dips 
7. 2X 100% EtOH for 3 dips 
8. 3X Xylene for  5 minutes each 
9. Coverslip with DPX 
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B5. Mounting tissue 
 
Figure B14. Example of mounted tissue 
 
1. Label slides using a hard, number 3 pencil with Mouse study name/number, 
stain, initials and date as shown above. 
a. This can be done ahead of time! 
2. Turn on light source, as this will help you see folds. 
3. Put a white paper towel or Kim wipe down if the tissue is stained, and use the 
black countertop if the tissue is not stained or very lightly stained. 
4. Using a paintbrush, mount tissue onto charged glass slides in mounting 
solution.   
5. Do not mount tissue at the very top of the slide, because the slide scanning 
microscope cannot image this region (shown above). 
6. Mount sections straight, flat, and without tears or folds 
7. Mount whole slices in mounting solution with the notch on the left. 
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8. Mount half brains in mounting solution as the left hemisphere. 
9. Mount tissue in order from top to the bottom horizontally through the brain. 
(just as it would come off in order as you section) Make sure you mount in 
straight lines, as this will help save a lot of time on the imaging and analysis 
of the stain. 
10.  Daub on a paper towel after you get each section on.  This pulls off water 
and helps the tissue stay on the slide better when submerged again in 
mounting solution to do the next piece. 
11.  Dry vertically, propped against something, with the bottom on a paper towel. 
12.  Once dry, lay out flat on a tray overnight. 
13.  Dehydrate the next day. 
14.  If dehydrating will be more than 48 hours away, cover to keep dust off the 
slides.  
 
 
160 
 
B6. Dehydrating and coverslipping for brightfield stains 
  
FigureB15. Dehydration dunker set-up. 
 
1. Put slides like an accordion into movable glass rack (fits 19 as shown in Figure 
B14).   
2. Be careful, the metal handle comes out! 
3. Rehydrate tissue in clean, fresh ddH20 for 3 minutes.  
4. Tilt rack sideways to remove as much water as possible, before moving to the 
next step, and each of the following steps. Dunk a couple times when first placing 
in the next step. 
5. 3 minutes in 25% Ethanol  
6. 3 minutes in 25% Ethanol  
7. 3 minutes in 50% Ethanol  
8. 3 minutes in 50% Ethanol  
9. 3 minutes in 75% Ethanol  
10. 3 minutes in 75% Ethanol  
11. 5 minutes in 95% Ethanol  
12. 5 minutes in 95% Ethanol  
13. 5 minutes in 95% Ethanol  
14. 5 minutes in 100% Ethanol  
 
 
161 
 
15. 5 minutes in 100% Ethanol  
16. 5 minutes in 100% Ethanol (change final 100% EtOH each time, rotate with the 
other two 100% EtOH containers, so they are all periodically being changed) 
17. 5 minutes in Histoclear (check clarity of slides, oily looking is normal, water 
droplets are not. If oily put back in 100% EtOH dunking 15 times followed by  3 
minutes) 
18. 5 minutes in Histoclear  
19. 5 minutes in Histoclear  
20. Leave rack and slides in Histoclear, remove one slide at a time. Do not let slides 
dry out before coverslipped. 
21. Drip 3 drops of DPX down slide using a glass stir rod.  
22. Angle the coverslip and let fall gently onto the slide. Allow DPX to spread 
beneath the coverslip, covering all the tissue. Remove ALL bubbles using a Q-
tip. 
23. Lay coverslipped slides flat on paper towels and dry overnight.  
24. Clean glass rod well and throw out Q-tip. 
25. After dried, scrape slides clean using a razor blade and wipe with Kimwipes. 
26. Slides should be placed in the appropriate slide box for long-term storage.  
27. Make sure to dump out dd20 and turn over to dry. 
 
Histoclear can be purchased from Fisher Scientific Cat# 50-899-90147.  
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B7. Analysis of staining 
B7.1 Drawing regions of interest 
1. Use program Zeiss NeuroQuant IAE-STI 
This program can be installed and used on any Window OS. 
 
Figure B16. Explanation of IAE-STI (A) Open TIFF file and set (B) magnification to 6-
10X.  Click on (C) the yellow roundish icon to draw region and (D) label the region. Click 
on (E) the red roundish icon to draw areas within the yellow region that should be 
excluded. Use (F) the cursor to remove single points. Use (G) the subtract points 
function to remove multiple points from the yellow region at one time. (H) Save file when 
finished. 
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2. Open the tif file (Figure B15A) associated with the slide you want to outline, not 
the folder. 
3. Zoom to ~6X magnification (Figure B15B).  Ideally you should be somewhere 
between 3-10X magnification, the most important thing is that you are consistent 
between all the samples you are processing for the analysis.  It helps to have it 
so the whole structure you are trying to outline is taking up most of your screen. 
4. Click on   the yellow roundish icon (Figure B15C). 
5. Using left clicks, trace the region of interest (ROI) you are trying to analyze.   
a. If you need to move to be able to trace the entirety of the structure you are 
outlining, be sure to use the arrows on the slides at the bottom of the 
screen. Don’t use the scroll wheel as that will alter the zoom. 
b. You will be able to correct this once you have the region outlined. 
6. Once your ROI is traced, right click to close the ROI. It should highlight bright 
yellow.  Label the region (Figure B15D) with a region initial and mouse number. 
7. If there are any obvious folds, tears, holes, etc you can exclude them from the 
ROI.  Use the red roundish button (Figure B15E), and in the same manner as the 
initial tracing, left-click around whatever needs to be excluded. Right click to 
enclose the red region. This region does not need to be labelled. 
8. To adjust the yellow area, click the cursor icon (Figure B15F) to adjust single 
points or the subtract region icon (Figure B15G) for multiple points.  Make sure 
the yellow region is selected, which will show red dots around the region. 
9. Once you’ve traced an ROI, press the save button (Figure B15H).  
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B7.2 Creating a segmentation file (Threshold positive stain) 
To analyze files double click Zeiss NeuroQuant IAE-STI on the desktop 
1. Open the tif file of a medium/dark stained image from the stain. 
 
 
Figure B17. Setting up a segmentation file in IAE-STI. Zoom in to (A) 1:1 ratio in an 
area of positive staining. Select (B) the hand cursor and right click on the positive stain 
(C). Use Visualize and clear/toggle to see the segmentation and region of interest 
respectively. Adjust the (F) VAL Range, (G) Saturation, and (H) Hue as needed. (I) 
Filter by area to remove dust and dirt.  (J) Save and (K) load segmentation files. 
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2. Zoom to 1:1 (Figure B16A) view on dark staining 
3. Select the “hand” cursor (Figure B16B).  
4. Right Click on positive stain (Figure B16C) until satisfied with the threshold of 
staining, click “Visualize” to update on image.     
5. Clicking  ”Visualize”/”Clear/Toggle” (Figure B16, D-E)  goes between segmentation 
and regions of interest 
6. Adjust “VAL Range”, “Saturation”,  and “Hue” (Figure B16, F-H) until satisfied, to 
filter out small dust/ dirt particles 
7. Adjust “Filter by Area” (Figure B16I) until smaller dust/ dirt are removed from 
analysis.  
8. Save the segmentation file by clicking “Save” (Figure B16J).  Name the 
segmentation file and save into a “Segmentation” folder you have made. File 
extension is:   *.iae .   
9. To load a saved segmentation file press “Load” (Figure B16K) in segmentation 
panel. Find the file, press open. 
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B7.3 To Analyze saved images with regional IDs 
1. Go to File on Menu bar 
2. Select “Batch Process” 
3. Click “Add Files…” 
a. Find the folder where the images are located  
b. Select only the ones with drawn areas (can be seen if you change file type 
to all) 
c. Click OK 
4. Check Combine Output to 1 CSV file – Name the file to be saved and save it in 
the segmentation folder which also has the segmentation file, to keep everything 
organized 
5. Load the segmentation(*.iae)  file under “User Color segmentation”  
6. Press “Begin”  
7. Analysis may take over night to process depending on the number of files you 
have and the areas that you are analyzing. 
Figure B18. Setting up batch process in IAE-STI. 
8. Once analysis is complete locate the .CSV file and convert to a .XLS for analysis 
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B7.4 Quantify the results 
1. First save .CSV file as Excel workbook, by Save As… Excel Workbook 
2. Sort by column B and only average regions which are labeled in this 
column, not including those labelled “TOTAL” in column A. 
3. Average the area ratios of each mouse for the region 
4. Standard deviations, ttests and standard errors should come from the 
averaged numbers of each group 
5. N should correspond to the number of mice  
 
Excel formulas: 
Formulas 
 
Average =average() 
standard 
deviation 
=stdev() 
standard error =stdev/(sqrt(count(N-1)) 
ttest =ttest(avg1,avg2,2,3) 
count =count(N) 
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B7.5 Representative images 
B7.5.1 Representative images using Mirax viewer 
Find the sections which best represent the results and convert scanned slide to a single 
image by using the Mirax Viewer or by using Mirax2Axiovision. 
1. Using Mirax Viewer (Can be installed on any computer): 
2. Draw regions needing to be exported inside a box by clicking on the box icon and 
drawing a box around the region of interest:  
Figure B19. Drawing a region to exprot in mirax viewer. 
3. Then export using: File>Slide Export> 
Figure B20. Exproting a region in Mirax viewer. 
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a. The higher magnification you need the region, the higher the til e size ratio 
you should pick.  Use a consitant ratio for representative images that are 
going to be used in one figure panel. 
b. Add the caption regions to the right side, which shows what is going to be 
exported. 
4. To draw a scale bar, you can do so by clicking creat distance measurement  
 
Figure B21. Creating a scale bar in Mirax viewer. 
 
a. When exporting, make sure to “Burn in annotations” to export with the 
scale bar  
Figure B22. Exporting a region with a scale bar in Mirax viewer. 
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B7.5.2 Representative images using Using Mirax2AxioVison batch processing 
(Can be installed on any Windos OS computer): 
1. Add Mirax files to be converted (*.mrxs). 
2. Set the Image layer resolution to “4” – four will always work. 3 can be  hit or miss, so 
it’s best to stick with 4 so the program is not super grumpy. 
3. Set tile size to “Single Image.” 
4. Designate the output directory—useful to designate a separate folder for the images 
to go in. 
5. Press begin. 
a. It may pop up warnings that the file outputs will be large, just press ok. 
Figure B22. Exporting whole slide images using Mirax2Axiovision
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B8 Solutions  
 
 
B8.1 Normal saline (NaCl 0.9%) 
1. Sodium Chloride (NaCl) – 18g 
2. Fill to 2000 mL ddH20 
3. Stored at room temperature  
4. no need to pH 
5. Filter before use 
6. Store at RT 
 
 
B8.2 Mounting solution 
1. 200 mL ddH20 
2. 100 mL PBS 
3. 100 mL 95% ethanol 
4. Store at RT on staining bench 
5. Filter after each use 
6. Remake when tissue sinks to the bottom quickly 
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B8.3 PBS 
1. Sodium chloride (NaCl) – 16.0g 
2. Sodium Phosphate Dibasic Anhydrous (Na2HPO4)- 2.3g 
3. Potassium chloride (KCl)– 0.4g 
4. Potassium phosphate (KH2PO4)– 0.4g 
5. Fill to 2000mL ddH20 
6. pH 7.4 
7. Filter before use 
8. store at RT 
 
 
 
B8.4 SPB 2X  
1. Potassium phosphate (KH2PO4)– 8.06g 
2. Sodium Phosphate Dibasic Anhydrous (Na2HPO4)- 20.0 g 
3. Fill to 1000mL ddH20 
4. pH 7.4 
5. Store in 4°C deli fridge 
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B8.5 4% Paraformaldehyde solution 
6. Make within 48 hours of use 
7. Make 10-20 mL/brain vial 
8. Add 10g PFA in 100 mL ddH20 to make a starting 10% solution 
9. Put in a flask with a stirbar 
10.  Heat and stir on a hotplate in hood at speed 1 and bring to 60°C with thermometer 
11.  Maintain 60°C for 5 minutes 
12.  While hot, Add NaOH (conc.) until clear (about 8 drops of concentrated solution) 
13.  Cool to room temperature 
14.  Add 125 mL of SPB 2x 
15.  pH 7.4 
16.  Bring final volume to 250 mL with ddH20 
17.  Filter 
18.  Store in 4°C deli fridge 
 
 
PFA Starting ddH20 NaOH SPB 2x Fill to with ddH20 
4g 40 mL ~3 drops 50 mL 100 mL 
10 g 100 mL ~8 drops 125 mL 250 mL 
20 g 200 mL ~16 drops 250 mL 500 mL 
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B8.6 Dehydration solutions 
1. 25% : 116 mL 95% ethanol + 324 ddH20 
2. 50% : 232 mL 95% ethanol + 202 ddH20 
3. 75% : 347 mL 95% ethanol +  93 ddH20 
4. 95% larger bottles 
5. 100% smaller bottles 
6. Put 220 mL in each dish 
7. Always use 95% EtOH to make dilutions 
 
B8.7 DPBS + Azide  
1. Start with PBS 2. CaCl 3. MgCl 4. Sodium Azide 
500 mL 0.068 g 0.025 g 0.325 g 
1000 mL 0.125 g 0.05 g 0.65 g 
2000 mL 0.27 g 0.1 g 1.3 g 
5. Keep CaCl and MgCl containers closed as much as possible, they absorb a lot of 
moisture from the air  
6. Make sure solution is still clear! 
7. Final pH 7.4 
8. Filter before use 
9. Chill before use, store in  4°C deli fridge 
10. Re-pH each time before using, this solution can sometime change pH 
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B8.8 TBS  
1. ddH20 2. Tris base 3. NaCl 4. HCl (10N) 
125 mL 0.75 g 1.1 g 0.4688 mL 
250 mL 1.5 g 2.2 g 0.9375 mL 
300 mL 1.8 g 2.64 g 1.125 mL 
500mL 3.0 g 4.4 g 1.875 mL 
600 mL 3.6 g 5.28 g 2.25 mL 
5. Filter before using 
6. Store at RT 
7. Final pH 7.6 
 
B8.9 Sucrose  
Volume % 1. ddH20 2. Sucrose 3. SPB 2X 
500 mL 10% 487.5 mL 50 g 12.5 mL 
1000mL 10% 975 mL 100 g 25.0 mL 
500 mL 20% 487.5 mL 100 g 12.5 mL 
1000mL 20% 975 mL 200 g 25.0 mL 
500 mL 30% 487.5 mL 150 g 12.5 mL 
1000mL 30% 975 mL 300 g 25.0 mL 
4. Store in 4°C 
Check solution for mold before using on tissue 
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APPENDIX C:  
 
ADDITIONAL PROTOCOLS 
 
 
C1.1 Sarkosyl insoluble protocol for rTg4510 mice 
  
1. Weight Brain, keep @ -80C as much as possible 
a. Weigh with utensils that have been chilled in dry ice and clean with EtOH 
between samples 
2. Use 10x the volume of homogenization buffer to homogenize brain (10uL = 1mg) 
a. Homogenize with dental tool or homogenizer at speed 5-6 (if over 1 mL of 
buffer needs to be used to homogenize bit, use 5mL tubes). Keep on ice, 
homogenize right away on ice. Do one sample at a time, not leaving the 
bit in buffer for more than a few seconds before homogenizing. 
Homogenize each sample for the same amount of time.  Usually 30 
seconds to 1 minute is sufficient for most samples. 
b. If sonication is needed, sonicate for 20 pulses. If not proceed to the step 3. 
3. Low-speed spin (LSS): 
a. Ultracentrifuge homogenate @ 13,000 x g for 15 minutes at 4ºC.   
4. Transfer supernatant to a new 1.5 mL tube, label this new tube LSS, Run BCA 
Protein assay on LSS. Keep at -80ºC.  
5. Take 400 µg of protein to start P3 fraction  
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a. You can start with as little as 200 µg from adult rTg4510 mice, but adjust 
the rest of the steps for any changes in starting protein amount. 
b. Make sure all the volumes are equal. 
1. Ultracentrifuge homogenate @ 100,000 x g for 23 minutes at 4ºC  (or 150,000xg 
for 15 min) 
a. Make sure you are using 100,000 x g tubes  
1. Transfer supernatant to a new 1.5 mL tube, label S1, run BCA, keep at -80ºC 
1. Homogenize pellet with 300uL Buffer B by using dental tool 
1. Ultracentrifuge Buffer B homogenate @ 100,000 x g for 23 minutes at 4ºC (or 
150,000xg for 15 min) 
2. Make sure you are using 100,000 x g tubes 
1. Keep P2 pellet in -80C, incubate supernatant with 1% Sarkosyl (final 
concentration) at 37ºC for 1 hour.   
a. Use 10% stock Sarkosyl Buffer 
b. 11 uL of 10% Sarkosyl for each 100uL solution = final concentration of 1% 
Sarkosyl solution 
1. Ultracentrifuge @ 100,000 x g for 45 minutes at 4ºC (or 150,000 x g for 30 min) 
a. Circle the around where the pellet should be 
b. The pellet will be invisible 
1. Transfer supernatant, from the opposite side of the tube from the pellet, to a new 
1.5 mL tube, label S2, keep at -80ºC 
1. Re-suspend Pellet in TE Buffer using dental tool in circle region 
a. 2 ul  TE buffer = 1 mg brain 
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15. Perform protein assay for S1 to determine protein concentration 
16. Run Westerns by using 3uL P3 and 2ug per sample of the S1 fraction. 
C1.2 Solutions for Sarkosyl insoluble preparation 
C1.2.1 Homogenization buffer: 
1/100 dilution (10uL per 1mL of Hsaio TBS)   
o Protease inhibitor for tissue from Sigma (keep at -20C)  
o Phosphatase inhibitor Cocktail I (keep at 4C) (or Phosphatase inhibitor 
Cocktail 3 can be used) 
o Phosphatase inhibitor Cocktail II (keep at 4) 
o PMSF (100mM) 
o With Hsaio TBS 
 C1.2.2 Buffer B: 
10mM Tris, pH 7.4 
0.8M NaCl 
10% Sucrose 
1mM EGTA 
1mM PMSF 
 (can make up stocks without PMSF and store at 4ºC, then just add PMSF when 
needed) 
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To make 3.75 mL Buffer B use: 
o 1mL 3M NaCl  
o 0.75mL 50% Sucrose 
o 37.5uL 1M Tris pH 7.4 
o 37.5 uL 100mM EGTA 
o 37.5uL 100mM PMSF 
o 1.89 mL dH2O 
  
C1.2.2 Hsiao TBS: 
o 500ml  
o 50mM Tris Base (3g) 
o 274mM NaCl (8g) 
o 5mM KCl (0.2g) 
o PH=8.0 
Can make a stock and store at 4°C. 
Use this buffer to dilute samples for westerns 
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C2. DNA isolation from tissue using QG-Mini80 
C2.1 DNA isolation using QuickGene DNA Tissue Kit S 
1. Reagents 
a. MDT-Tissue lysis buffer 
i. Store at RT 
ii. Shake before use 
iii. If precipitates form, heat to 55°C and cool to RT before use 
b. EDT- Proteinase K 
i. Keep at 4°C 
c. LDT- lysis buffer 
i. Store at RT 
ii. Shake before use 
iii. If precipitates form, heat to 37°C and cool to RT before use 
d. WDT- wash buffer 
i. Store at RT 
ii. Supplied as concentrate, add 160 mL of 100% EtOH before first use 
and check box 
iii. Close the lid tightly so EtOH does not evaporate after use 
e. CDT- elution buffer 
i. Store at RT 
ii. Shake before use 
f. RNase buffer 
i. This does not come with kit and will need to be purchased separately 
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ii. Make sure the RNase buffer does not have DNase activity or it will 
need to be heat inactivated 
2. Weigh out 10-15 mg of frozen tissue into an RNase/DNase free 1.5 mL tube. 
a. Add 180 µL MDT  
b. Add 20 µL EDT  
3. Incubate at 70°C overnight, until tissue is completely lysed (use 55°C if isolating 
DNA from tail tissue) 
a. Lysis should continue for about 16 hours 
b. Can be extended if samples are not fully lysed 
4. Once lysed, spin at 8,000 x g (10,000 rpm) for 3 minutes at RT 
a. Do this 8 samples at a time if continuing to purification using QG-Mini80 
5. Transfer supernatant into a new RNase/DNase free 1.5 mL tube 
6. Treat with RNase 20 µL of 20 mg/mL is sufficient for 15 mg samples. 
a. Vortex for 5 seconds 
b. Flash spin down 
c. Incubate at RT for 2 minutes 
7. Add 180 µL LDT 
a. Vortex for 15 seconds 
b. Flash spin down 
8. Incubate at 70°C for 10 minutes 
a. Flash spin down 
9. Add 240 µL of 100% EtOH 
a. Vortex for 15 seconds 
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b. Flash spin down 
10. This is your lysate; continue to purification right after this step. 
C2.2 DNA purification using QG-Mini80 
1. Set up the machine 
a. Put waste tubes in apparatus 
b. Make sure tube adaptors are in place, and add in collection tubes 
c. Insert cartridge holder into the wash position (closest to you, should be 
able to see WASH label) 
d. Add cartridges to the holder 
2. Transfer each lysate into a separate cartridge 
3. Apply pressure using QG-Mini80 
4. Wash each sample with 750 µL WDT 
5. Apply pressure using QG-Mini80 
6. Wash each sample with 750 µL WDT 
7. Apply pressure using QG-Mini80 
8. Wash each sample with 750 µL WDT 
9. Apply pressure using QG-Mini80 
10. Move cartridge holder into the elution position (furthest from you, should not be 
able to WASH label) 
11. Add 200 µL CDT 
a. Incubate 90 seconds at RT 
12. Apply pressure using QG-Mini80 
13. This is your purified genomic DNA. Cap and label tubes. 
